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Understanding the effect of the environment on human health has benefited from progress
made in measuring the exposome. High resolution mass spectrometry (HRMS) has made it
possible to measure small molecules across a large dynamic range, allowing researchers to study
the role of low abundance environmental toxicants in causing human disease, including
examining their effects on biochemistry. Alzheimer’s disease is the most prevalent
neurodegenerative disease in the world. While aging is the largest risk factor of the disease,
evidence of risk factors for dementias show that lifestyle choices and the environment may
modify disease onset and alter the projected prevalence. Observational epidemiological studies
have linked exposure to the persistent pesticide dichlorodiphenyltrichloroethane (DDT) with
increased risk of Alzheimer’s disease (AD).
In Chapter 2, using an aging cohort based in Washington Heights and Inwood in Northern
Manhattan, I investigated systemic biochemical changes associated with Alzheimer’s disease
(AD). Small molecules in plasma were measured in 59 AD cases and 60 healthy participants of
African American, Caribbean Hispanic, and non-Hispanic white ancestry using untargeted
liquid-chromatography–based ultra-high-resolution mass spectrometry. Metabolite differences
between AD and healthy, ethnic groups and apolipoprotein E gene (APOE) Y allele status were
analyzed. Untargeted network analysis identified pathways enriched by AD-associated
metabolites.
Then, in Chapter 3, using the genetically tractable nematode model Caenorhabditis
elegans, I investigated whether DDT can exacerbate AD-related pathology. DDT is a persistent
organic pollutant which, despite its ban in 1972, can be detected in the blood of most people in
the U.S.. I investigated whether DDT can exacerbate AD-related pathology using a transgenic C.
elegans strain that expresses a mutant tau protein fragment that is prone to aggregation, as well as
a mutant strain expressing a non-aggregating form of tau protein. DDT restricted the growth in all
strains; however, the restriction was more severe in the aggregating tau transgenic strain. Further,
I found that DDT exacerbates the inhibitory effects of aggregating tau protein on basal
mitochondrial respiration, and increases the amount of time the worms spent curled/coiled.
High-resolution metabolomics in the whole worm suggests that DDT reduces levels of several
amino acids but increases levels of uric acid and adenosylselenohomocysteine. Surprisingly,
developmental exposure to DDT blunts the lifespan reduction caused by aggregating tau protein
suggesting a mitohormetic effect of the “double-hit” from DDT and aggregating tau protein or an
antagonistic effect which could ultimately turn on lifespan extension pathways. Our data suggest
that exposure to DDT likely exacerbates the mitochondrial inhibitory effects of aggregating tau
protein in C. elegans. DDT may mimic some of the mitochondrial inhibitory effects induced by
increased tau protein aggregation, suggesting that the genetic and environmental insult converge
on a common mitochondrial inhibitory pathway, which has been associated with AD in several
other studies.
Finally, in Chapter 4, I determined changes in global metabolism associated with
aggregating tau protein in both C. elegans and humans. We performed high-resolution
metabolomic analysis on cerebrospinal fluid (CSF) and plasma obtained from patients of AD and
mild cognitive impairment, and cognitively normal controls. Using a transgenic strain of C.
elegans which expresses aggregating tau protein in all neurons, I studied the effect of aggregating
tau protein on metabolism using high-resolution metabolomic analysis in the whole worm. In the
population study, I found >300 features associated (p < 0.05) with phosphorylated tau levels in
CSF. Metabolic pathway enrichment identified alterations in fatty acid and amino acid
metabolism. Worms expressing aggregating tau showed >900 features altered. Pathway
enrichment suggested alterations in glycerophospholipid, fatty acid and amino acid metabolism
pathways. To determine which metabolic features are altered in both species, I analyzed
annotated features for overlap. Five metabolites were concordant between human plasma and C.
elegans, and four concordant between human CSF and C. elegans. Thus, in this analysis I provide
evidence in support of using C. elegans to study changes in global metabolism associated with
Alzheimer’s disease.
In conclusion, using liquid and gas-based chromatography coupled with high-resolution
mass spectrometry, we can measure levels of endogenous and exogenously derived small
molecules in different biological matrices. By using the appropriate study design, we can identify
candidate molecules and biological pathways associated with environmental exposures or disease
in human populations. These candidates can be followed up by exposing an appropriate C.
elegans strain: transgenic strains, mutant strains, or strains that are susceptible to RNAi based
knockdown. Given their short life cycle and being amenable to high-throughput behavioral
assays, they can readily provide functional and molecular readouts of the perturbation. The
findings can provide leads for relevant policy around environmental exposures, understanding
mechanisms of toxicity and disease, and identifying potential therapeutic targets.
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Chapter 1: Pursuing the totality of exposures
1The role of the environment in disease etiology has received increased attention over the past
several years. The genome and genetic variations account for far less of disease burden in the
population than was previously thought and the variation in population burden of disease is now
largely attributed to non-genetic factors. A meta-analysis of 2,748 twin studies reported that the
environmental contribution to thousands of complex human phenotypes was nearly equal to that
of genetics (Polderman et al. 2015). A study in monozygotic twins found that the average genetic
risk attributed to 28 chronic diseases was just 19% (range: 3-49%) (Rappaport 2016).
The environment encompasses a broad range of factors in the physical world. It includes but is
not limited to: dietary factors, exposure to infectious and synergistic organisms, toxicant exposures
through various media and routes, the built environment, neighborhood level characteristics like
access to healthy food, parks, and also includes structural policies that control access to healthcare,
and influence other health related behaviors and choices. Given how diverse the environmental
health umbrella is, it is not surprising that there are several definitions of what the environment
constitutes. For the purpose of this disseretation, I define the environment as all non-genetic factors
that can be measured in the human body which may contribute to variability in disease risk and
burden in an individual and in the population.
1.1 Historical perspective
The effect of the environment on human health has been suggested for millennia. In 400
BC, Hippocrates penned “On Airs, Waters, and Places”, discussing the possible role of air and
1Portions of this material were published as: 1. Kalia, V., Barouki, R., and Miller, G.W. (2020). The Exposome:
Pursuing the Totality of Exposure. In A New Paradigm for Environmental Chemistry and Toxicology: From Concepts
to Insights, G. Jiang, and X. Li, eds. (Singapore: Springer), pp. 3–10; 2. Kalia, V., Walker, D.I., Krasnodemski, K.M.,
Jones, D.P., Miller, G.W., and Kioumourtzoglou, M.-A. (2020). Unsupervised dimensionality reduction for exposome
research. Current Opinion in Environmental Science & Health.
1
water quality, and climate on human health (Hippocrates et al. 1881). The ancient Romans were
aware of the adverse effects of exposure to lead from pipes that conducted water. Vitruvius, a
Roman architect and civil engineer, noted that using earthen pipes to transport water would be
safer for health than using pipes that contained lead (Hodge 1981). In the 19th century, public
health efforts were focused on preventing exposure to infectious agents in the environment. Using
epidemiological approaches, John Snow discovered a point of water contamination as the cause of
a cholera epidemic in London in 1854 (Ruths 2009). These findings and others led to changes in
water distribution systems, sewage treatment and food handling in London. Water and sanitation
remain important environmental determinants of health in many developing countries.
Most modern environmental epidemiology studies begin with observations of regional dif-
ferences in disease rates. Adverse health effects associated with exposure to air pollution were
discovered through atmospheric inversion phenomena that led to greater exposure for an extended
period over specific geographic regions like Donora in the USA (1948), London in the UK (1952),
and in the Meuse Valley in Belgium (1930) (Bell, Davis, and Fletcher 2004; Jacobs, Burgess, and
Abbott 2018; Nemery, Hoet, and Nemmar 2001). Several other ecological studies were seminal in
establishing relationships between air pollution exposure and adverse health outcomes (Dockery
et al. 1993). In the 1960s – 70s, research focus shifted toward chemical and physical agents in the
environment that can affect human health. Several researchers and public health agencies studied
the effect of exposure to volatile organic compounds, metals, particulate matter, pesticides, and ra-
diation on health. Books like the Silent Spring (1962) and Our Stolen Future (1996) were critical in
raising public awareness in the US on the societal cost of exposure to persistent organic pollutants
and endocrine disrupting chemicals. Recently, the effect of natural disasters, the built environment
and global climate change on health are also being investigated (Cascio 2018; Kouadio et al. 2012;
Patz et al. 2014; Watts et al. 2018).
Increased research efforts in precision medicine have benefited environmental health research
immensely. Advances in molecular techniques have made it possible to study gene x environment
interactions that can alter disease risk. The Human Genome Project provided tools to make en-
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vironmental determinants of health personalized, offering the opportunity to discern how certain
genotypes may be more susceptible to effects of an environmental exposure (Collins, Morgan, and
Patrinos 2003). Apart from the geographical and genotypic context, the life stage during exposure
can also alter disease risk and susceptibility to an exposure. The developmental origins of health
and disease (DoHAD) hypothesis has led to the discovery of epigenetic transfer of information
from parent to offspring and unveiled the vulnerability of the fetus to environmental toxicants and
their effect on development and health in later life (Barker 2007).
Advances in environmental chemistry and toxicology have been critical in understanding en-
vironmental contributors of human disease. Environmental epidemiology uses both approaches to
assign exposure and to determine biological plausibility of observed association between exposure
and outcome.
1.2 The exposome
In order to understand mechanisms by which environmental exposures can affect human health,
researchers and regulators have studied exposures in great detail and described the effect of expo-
sure in isolation to a number of chemicals on various health outcomes. However, real world expo-
sures do not occur in isolation and are accompanied with other exposures and context specific fac-
tors. Besides, human interaction with the environment is lifelong, constant, and spatiotemporally
dynamic. Historically, most epidemiological and toxicological studies have not accounted for this
chronic, low dose exposure to environmental chemicals. To account for this reality, Christopher
Wild formally introduced the concept of the exposome in 2005. He defined it as the “life-course
environmental exposures (including lifestyle factors), from the prenatal period onwards” (Wild
2005). The formal definition has undergone several revisions but most versions agree that the ex-
posome comprises the entire set of lifelong environmental exposures and the biological response
associated with these exposures (Miller and Jones 2014; Miller 2013; Rappaport 2011; Wild 2012;
Niedzwiecki et al. 2019b). Investigating the biological response to an exposure accounts for tox-
icity mechanisms and inter-individual variability in response. It also allows for measurement of
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transient exposures that would be invisible through traditional approaches of exposure assessment.
Given that the environment is dynamic across the life course, assessing all exposures appears a
daunting task. However, recent advances in methods bring optimism and avenues for creativity in
the field.
1.2.1 Tools to monitor the exogenous exposome at the population level
Remote sensing is the science of gaining information on objects from a distance and have been
used to identify exposures related to the urban environment. Specifically, these techniques can
be used to estimate population level exposure to air pollution, changes in temperature, amount
of green space assessed using a normalized difference vegetation index, and provide information
on outdoor light-at-night exposure (Kloog et al. 2008; Larkin and Hystad 2018; Markevych et
al. 2017; Rybnikova, Haim, and Portnov 2016; Turner et al. 2017). Further, remote sensing data
from a number of satellites have been integrated to determine global fine particulate matter con-
centrations (Donkelaar et al. 2010).
Mobile and stationary sensing monitors are usually used to make exposure measurements in
specific locations. They can be a part of national networks of measurement or be related to study-
specific measurement campaigns. National networks tend to have limited coverage but can be
used as part of a distributed sensor network, which uses low cost sensors to fill in spatial gaps
that national networks are unable to meet. These have been implemented in West Oakland, Cali-
fornia (West Oakland Air Quality Study), and in Eindhoven, The Netherlands (AERIAS Project).
However, low cost sensors still require rigorous validation, limiting their widespread application
(Curto et al. 2018). Mobile measurement campaigns have been implemented more recently in a
few places, like Karlsruhe, Germany, and Zurich, Switzerland (Hagemann et al. 2014; Hasenfratz
et al. 2015).
Modeling approaches find utility in distilling GIS and satellite data which maybe incomplete
in time or spatial resolution. Models such as land use regression, kriging, and maximum entropy
models have been considered by researchers and will need to be elaborated (Jerrett, Gale, and
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Kontgis 2010). Data generated from population level exposure assessments provides opportunity
to create ecological studies that can provide links between exposure and population health. Most
of these data sources however are ineffective at determining individual exposure levels. They will
need to be integrated with individual level measures for validation.
1.2.2 Tools to monitor the exogenous exposome at the individual level
External sensors can be used to track a myriad of personal information. Personal location data
obtained through GPS devices enable integration of exposure maps with individual location mark-
ers to obtain personal exposure estimates (Asimina et al. 2018). Accelerometers and other activity
tracking personal devices like Jawbone, Fitbit, Apple Watch, and Polar (Loh et al. 2017) can be
used to ascertain both external exposures and certain lifestyle factors related to exercise and diet.
Personal sensing technologies can also be used to assess air pollution exposure, changes in am-
bient temperature, and presence of green space (Nieuwenhuijsen et al. 2014). Passive dosimeters
like silicone wristbands can also be used for personal exposure assessment and provide valuable
semi-quantitative information on several chemicals.
Smart phone-based sensors and assessments can integrate data from personal sensors like ac-
celerometers, GPS, barometers, thermometers, and ambient light sensors to record personal expo-
sures. Their high penetrance worldwide provides a unique opportunity to obtain large amounts of
personal data from diverse individuals (Murphy and King 2016; Wel et al. 2017).
Personal sensors to monitor heart rate, glucose levels, blood pressure, muscle activity, body
temperature, and sweat production are being developed and will require validation before imple-
mentation in large population studies. Compared to measurements of external exposure, individual-
level data is more actionable, can be used for personalized advice, and can be related to internal
dose and associated biological responses.
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1.2.3 Tools to measure endogenous response
Techniques in molecular biology have shown exponential advancement in the last three decades.
These advances have increased the resolution at which biological response to perturbations from
environmental exposures is measured. Exposures to environmental factors can induce local and
global changes in gene expression, enzyme activity, metabolite pathway alterations, and protein
synthesis/folding. Deep molecular phenotyping can provide information on acute biological re-
sponses and also provide measures of long-term changes in physiology which can be viewed as
markers of exposure memory (Go and Jones 2016; Jeanneret et al. 2014; Weinhold 2006).
Metabolomics. The metabolome comprises of all the small molecules in a biological matrix
that are < 2,000 daltons in molecular mass. It is thought of as the functional output of genes
and proteins, and their interaction with the environment. Recent advances in mass spectromet-
ric techniques have made it possible to capture previously undetected small molecules, with es-
timates suggesting the metabolome may comprise more than 1 million metabolites or features
(Uppal et al. 2016). Chemical signals derived from a biological sample can arise from endogenous
metabolism, environmental chemical exposures, diet, the microbiome, personal care products, and
drugs (Jones 2016; Liu et al. 2016; Petrick et al. 2017; Walker et al. 2019; Walker et al. 2016).
Using an untargeted approach, metabolomics can expand surveillance of environmental chemicals,
detect new xenobiotic chemicals, and identify unknown pollutants (Bonvallot et al. 2013; Jamin et
al. 2014; Roca et al. 2014). Historically, metabolomics has not focused on those exogenous chem-
icals, but recent efforts are increasing the identity of environmental chemicals through these untar-
geted approaches. By simultaneously measuring exposure and biological response, metabolomics
offers the opportunity to link exposure to molecules associated with the exposure. While the iden-
tity of most chemical features that are measured using untargeted high-resolution metabolomics
remain unknown, the technique offers a powerful opportunity for hypothesis generation and iden-
tification of unknown chemicals of interest related to a health outcome.
Transcriptomics. Gene expression is the process by which genetic data encoded by DNA
is transcribed to RNA, which then initiate and direct protein synthesis in a cell. Cellular func-
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tion regulation involves a complex series of steps that control the amount of RNA, and in turn,
protein that is synthesized. Thus, exposures that alter functional regulation in the cell can be de-
tected using transcriptomic and metabolomic analyses. Chemical exposures have been linked with
distinct gene expression profiles that have been seen in humans and model organisms (Hamadeh
et al. 2002). Transcriptomic analyses in human samples involve DNA microarray hybridization
which uses 40,000-50,000 molecular probes to seek RNA transcripts (Fry et al. 2007; McHale
et al. 2009; Spira et al. 2004). Next-generation sequencing has made it possible to measure the
effect of exposures on different types of RNA in a sample, including mRNA, microRNA, small
interfering RNA, and long non-coding RNA. Databases that curate gene expression profiles across
different exposures and model organisms provide opportunities to compare experimental data with
previously generated gene expression profiles (Grondin et al. 2018).
Proteomics. Protein measurement can elucidate signaling, inflammation, oxidative stress, and
tissue damage in a biological sample. Levels of proteins and their post-translational modifications
are closer to function than gene expression data. Measuring proteins can be targeted using enzyme
linked immunosorbent assays (ELISA), or newer multiplexed bead-based assays that are capable
of measuring more than 50 proteins in a small amount of biological material (Elshal and McCoy
2006; Tighe et al. 2015). Untargeted proteomics using high-resolution mass spectrometers though
insightful is challenging because of difficulties in detecting low abundance proteins. Chemical
exposure to reactive electrophiles has been achieved through protein adductomic platforms, which
can measure more than 100 human serum albumin adducts at the Cys34 site. Protein adductomics
has been used to assess exposure to lifestyle factors, indoor air pollution, and ambient air pollution
(Grigoryan et al. 2016; Liu et al. 2018; Rappaport et al. 2012).
Epigenomics. Epigenetic changes on DNA can alter gene expression. These changes can
occur through addition or removal of methyl groups on CpG dinucleotides, or through histone
modifications. These modifications can be long term and have the potential to be transferred to
the next generation if they occur in germ cells. Different stressors including chemical exposures
can lead to specific epigenetic signatures that persist even after the stressor has been removed
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(Fernandez et al. 2012). Thus, epigenetic profiles can be used to monitor exposure history and to
assess acute or chronic stress (Go and Jones 2016, 2014). High-throughput assays based on parallel
sequencing of DNA with bisulfite conversions can measure up to 850,000 CpG sites within the
human genome. Epigenome-wide association studies have revealed distinct methylation patterns
associated with chemical exposures, providing insight into mechanisms underlying the biological
responses (Bollati et al. 2007; Hou et al. 2012; Seow et al. 2014).
Multi-omics assessment of the exposome. Information from different layers of the biochem-
ical dogma can be integrated to paint a holistic picture of biological response to an environmental
perturbation (Figure 1.1). Using approaches from systems biology, we can gain a deeper under-
standing of environmental influences on human health by integrating across epigenomic, tran-
scriptomic, proteomic, and metabolomic changes associated with exposures. The integration of
high-dimensional data has benefited from development of statistical approaches that identify inter-
actions among biological response networks (Kalia, Jones, and Miller 2019; Uppal et al. 2018).
The continued use of deep molecular phenotyping of cohort studies will generate data needed to
spur new discoveries and methods (Barouki et al. 2018; Carvaillo et al. 2019; Li et al. 2017; Vineis
et al. 2017; Vrijheid 2014).
1.2.4 Considerations in measuring exposure and biological response
Several lessons have been learned from environmental epidemiology about associations be-
tween exposure and disease. Investigators have recognized the importance of accuracy and preci-
sion while measuring exposure. Accurate exposure assessment is essential to detect and quantify
a dose-response relationship. Inaccuracy can lead to mis-measurement of a continuous exposure
measure, or can lead to misclassification of a dichotomous exposure status, which can severely
bias results toward the null. Using biomarkers of exposure has several advantages: 1. Detec-
tion of the biomarker proves absorption of the compound, 2. It accounts for bioavailability of
the compound, 3. It integrates measures over all routes of exposure. However, it remains hard
to tell where in the environment the compound came from, positing the need to compare internal
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dose data with data collected from external monitors and measurements. Further, since biomarker
collection is expensive and relies on access to biological matrix availability, we can also validate
other less expensive measurement methods by validation against biomarkers measured in a subset
of the population. Epidemiological studies that provide causal interpretation of observations have
good study designs. These study designs account for all variables that can confound relationships
between exposure and response, and provide the means to uncover temporal relationships.
1.3 The exposome and toxicology
More than 85,000 chemicals are registered with the EPA for manufacture, import, and use
in commercial products (see this EPA TSCA update). Approximately 112,000 chemicals and
compounds are registered with the US Food and Drug Administration as drugs or food additives
(Niedzwiecki et al. 2019b) . A majority of these chemicals have little information on their health
effects at low concentrations and their influence as complex mixtures seen in real-world scenarios.
This poses a significant challenge that requires expertise across several disciplines. Toxicologists
have been systematically working through this list of chemicals that contribute to the chemical ex-
posome. High throughput screening assays have gained popularity for their efficiency and the high
resolution of data they produce. While conserving time, they provide valuable insight that guide
researchers toward the affected organ system or pathway that may be perturbed due to an exposure.
The National Toxicology Program in the US has been leading a shift in current toxicological re-
search, moving away from in vivo testing and incorporating high-throughput in vitro assays, model
organisms, and computational models to study adverse effects of exposure to mixtures of chemicals
(Council 2007). Some of these methods are discussed below.
Structure activity relationship (SAR). This method uses physical and chemical character-
istics to predict toxicity based on the similar-property principle, i.e., similar structure = similar
biological activity (Tong et al. 2003). These methods can be quantitative (mathematical model-
ing) or qualitative (recognize substructures that afford toxic properties). They have found utility in
predicting toxicokinetics, half-lives, and the ability of chemicals to cross the blood brain barrier.
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In vitro testing. Human cell lines and animal cell lines transfected to express human genes can
be used to create assays to measure molecular changes due to different exposures. Modifying assay
parameters and changing culture condition can alter the context of exposures to answer specific
biological questions. As an example, in vitro cell lines have been used to study the effect of
exposure to mixtures on receptor ligand binding and activation. A group of researchers found that
at low concentrations, a combination of two known pregnane X receptor (PXR) ligands resulted in
a synergistic effect on activation of the receptor, which was not observed with each chemical alone.
The researchers suggested that the two ligands together form a “supermolecular ligand” within the
ligand binding pocket of the nuclear receptor (Delfosse et al. 2015). Findings such as these support
the exposome concept in toxicological studies.
Cell-based in vitro assays can be used for high-throughput screens which offer an economical
way to screen a large number of chemicals in a short period. These screens are widely accepted in
the pharmaceutical industry to predict therapeutic action, pharmacokinetics, interactions with en-
zymes, biotransformation, metabolic products, and have been used to rapidly detect interactions of
drugs with genetic polymorphisms. Further, all methods described to measure biological response
(section 1.2.3.) can be applied on a cellular level to ascertain changes in gene expression, protein
expression, metabolism, and epigenetic modifications due to an exposure.
Model organisms. While cell-based assays serve as excellent screening tools, single cells
don’t represent complex tissue interactions of a whole organism. To this end, model organisms
like Caenorhabditis elegans (worms) and Danio rerio (zebrafish) have been gaining popularity as
toxicological models. The short generation times of C. elegans make them excellent models to
study aging and life course specific changes in response to exposure. Several molecular pathways
have been conserved across evolution making discoveries and observations in these models rele-
vant for the human context. In a metabolomic study, Jones and colleagues described changes in
metabolism in C. elegans as a result of exposure to a mixture of the heavy metal nickel and the pes-
ticide chlorpyrifos. The authors noted changes in metabolism of the branched-chain amino acids
and tricarboxylic acid cycle intermediates. They also found changes in reproduction (brood size)
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due to exposure to this mixture of toxicants (Jones et al. 2012).
1.4 The HRMS framework for the exposome: data analysis considerations
In this dissertation, I define the exposome as the sum of environmental exposure and the bi-
ological response induced by these environmental exposures. This definition assumes that mean-
ingful environmental exposures that affect human health will produce a biological response which
will be reflected in alterations to endogenous metabolic processes. Thus, measurements of small
molecules in a biological matrix will allow us to measure this exposomic profile and assess bio-
chemical changes that accompany exposure on a systems level. Using techniques from metabolomics,
we can understand the biological effect associated with the exposome. For example, Walker et al.
measured the exposomic profile of trichloroethylene (TCE) exposure among factory workers and
found chlorinated metabolites in the plasma of factory workers that were correlated with markers
of immune and kidney function along different parts of the pathway of TCE toxicity (Walker et
al. 2016). HRMS can also be leveraged to measure the sum of environmental chemicals in a ma-
trix. By coupling gas chromatography to HRMS, researchers have measured numerous chemicals
of interest in a single sample simultaneously, e.g., the US Environmental Protection Agency’s ring
trial, wrist band studies, etc. (Sobus et al. 2019; O’Connell, Kincl, and Anderson 2014).
Exposomic data from HRMS are high-dimensional and complex. When untargeted methods
are used to characterize the exposome, the number of chemical signals can be greater than 100,000
(Vermeulen et al. 2020). These data tables represent the primary input for bioinformatic and bio-
statistical analysis to evaluate biological meaning and to determine exogenously derived chemicals
that may be of relevance to an outcome of interest. Since detected analytes are not annotated a
priori, the results from HRMS contain information on each detected ion (a feature). Each fea-
ture is characterized by its mass-to-charge ratio, the retention time at which the compound eluted
from the chromatographic column, and its abundance in the sample. Some features may arise
from the same parent compound but during ionization may lead to formation of multiple ions with
different masses, but same retention times. Therefore, the feature table may contain degenerate
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Figure 1.1: Untargeted metabolomics workflow for exposome research. Created with BioRen-
der.com
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features which will be highly correlated since they arise from the same parent compound. Thus,
correlation is present not only due to exposure sources and biological processes, but also arises
from the analysis itself (Alonso, Marsal, and Julià 2015). This forces us to deal with the “curse
of dimensionality”, and to capture the essence of the data generated (Bellman 1972). Given the
high correlations across chemical exposures, single chemical association studies are not appropri-
ate, with implications for health that are missed using a “candidate” approach. Furthermore, high
correlation compounds correction for multiple testing, decreasing study power and inflating the
potential for false negatives. Several tools have been developed (Djoumbou-Feunang et al. 2019;
Ruttkies et al. 2016) which can help predict and identify unknown chemical signals measured in
human and environmental samples. Efforts are underway to use high-resolution mass spectrom-
eters to characterize all chemicals present in an environmental sample. Methods have also been
developed to identify “known unknown” chemicals using spectral fragmentation patterns that can
help deduce chemical structure and identity (Gago-Ferrero et al. 2015; Schymanski et al. 2015).
Data dimensionality reduction approaches produce a manageable number of variables, allow
for better visualization, remove redundant and uninformative variables, and reduce computational
burden (Xue, Stahura, and Bajorath 2004). Several techniques have been described that reduce
the size of the data table while minimizing loss of information, describing the essence of the data
generated. While dimensionality reduction removes redundant information, such as multiple ions
present from one chemical or highly correlated metabolites from the same biological pathway,
these redundant signals are informative when evaluating chemical identifications and evaluating
systemic biological response to exposure (Boccard and Rudaz 2014). Further, simply creating
new variables that are linear combinations of other variables can hinder interpretability of re-
sults. Chemical risk assessment is difficult to accomplish with linear combinations of multiple
chemicals and researchers must attempt to report interpretable results from high-dimensional data.
Lastly, generalizing latent structures from observed data should be performed cautiously. As noted
by Alexandre Dumas (Junior), “all generalizations are dangerous, even this one” (Child 2006).
Thus, exposome research requires approaches to analyze the data that are as sophisticated as the
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approaches used to generate the data.
In Chapter 2, I present findings from the use of high-resolution metabolomics to discern un-
derlying metabolomic/exposomic features associated with Alzheimer’s disease (AD) and how this
varies under different contexts of ethnicity and underlying genetic susceptibility conferred by the
Y 4 allele of the APOE gene.
Several environmental factors have been associated with Alzheimer’s disease, including diet,
air pollution, and exposure to several toxicants (DeKosky and Gandy 2014). Richardson and
colleagues (Richardson et al. 2014) found higher levels of a metabolite of the legacy pesticide
dichlorodiphenyltrichloroethane (DDT) in patients with Alzheimer’s disease. This finding was
corroborated by data (unpublished observations) from the Miller lab, wherein, through untargeted
metabolomic analysis, Megan Niedzwiecki found a metabolite of DDT to be higher in the plasma
of patients with Alzheimer’s disease. In chapter 3, I follow-up on these findings using the in vitro
nematode model, Caenorhabditis elegans (C. elegans). Using transgenic strains, I expose C. el-
egans to DDT and assess the ability of DDT to exacerbate underlying proteotoxicity exerted by
aggregating tau protein. A number of signaling pathways that act as master regulators of aging
and lifespan are conserved in yeast, nematodes, flies, and mammals (Bishop, Lu, and Yankner
2010). The Miller Lab has adopted the nematode C. elegans (worms) as a model to study ag-
ing, cognitive function, and neurodegeneration. Worms have a complex nervous system in which
the major mammalian neurotransmitter/neuropeptide signaling components are conserved. They
have orthologs for 60-80% of human genes, including highly conserved metabolic, transcriptional,
and protein biochemical machinery (Corsi, Wightman, and Chalfie 2015). The organism’s short
lifespan (2-3 weeks) makes it ideal to study aging and age-related pathology (Ardiel and Rankin
2010; Arey and Murphy 2017). Many long-lived mutants have been identified in C. elegans (Uno
and Nishida 2016) and the insulin/insulin-like growth factor-1 signaling (IIS) pathway, the first
established lifespan-regulating signaling pathway, was discovered in C. elegans, supporting its use
in studies of aging (Kenyon et al. 1993). In addition, C. elegans also have conserved metabolic
components. Worm mitochondria show close structural and functional conservation to mammalian
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mitochondria (Murfitt, Vogel, and Sanadi 1976) and pathways of intermediary metabolism are also
highly conserved (O’Riordan and Burnell 1989). C. elegans is a useful model system to study
neurodegenerative diseases, including AD (Link 2006).
In Chapter 4, I assess the relationship between tau protein and metabolism measured in three
different matrices: 1. In whole worms expressing aggregating tau protein in all neurons, 2. In hu-
man CSF and 3. In human plasma, both from patients of Alzheimer’s disease, MCI and cognitively
normal controls. I then compare tau-protein metabolic features measured in whole worms and in
human CSF to determine which, if any, features associated are common to both organisms.
In Chapter 5, I discuss results from Chapters 2-4 and conclude my findings. I suggest the
utility of the C. elegans model to confirm findings made in epidemiological settings and discuss
approaches needed to ascertain the environmental drivers of AD using an exposomic framework.
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Chapter 2: Differences in plasma metabolites related to Alzheimer’s disease,
APOE Y4 allele, and ethnicity
2.1 Introduction
1All around the world, the proportion of populations over the age of 65 is increasing owing to
the many advances in public health and medicine. However, with longer lifespans, come greater
number of people living with diseases associated with aging. Neurodegenerative diseases like
Alzheimer’s disease (AD) pose a grave concern to the current and future elderly populations. The
disease has a debilitating effect in people and presents a heavy emotional and economic burden on
families and societies (Chang et al. 2019). In 2014, 5 million people in the US were living with
AD. By 2060, this number is projected to grow to 13.9 million (Matthews et al. 2019).
In 1907, Aloysius “Alöis” Alzheimer first described the symptoms of a 51-year-old woman,
Auguste Deter, whom he was treating in Frankfurt, Germany (Figure 2.1) (Alzheimer et al. 1995).
This is likely the first neuropsychological assessment of the disease, which is named after him.
After his patient’s demise, he used the then cutting-edge silver stain technique to analyze her brain
histopathologically and found the presence of plaques and intraneuronal tangles (Bondi, Edmonds,
and Salmon 2017). It is now well established that clinically, AD manifests as dementia, a pro-
gressive deterioration of memory and cognitive function (Van Cauwenberghe, Van Broeckhoven,
and Sleegers 2016) and pathologically, it is characterized by severe neuronal loss, aggregation
of amyloid-V (AV) in extracellular senile plaques, and formation of intraneuronal neurofibrillary
tangles consisting of hyperphosphorylated tau protein.
Despite the disease first being identified more than 110 years ago, the understanding of the
1Portions of this material were published as: Vardarajan, B.*, Kalia, V.*, Manly, J., Brickman, A., Reyes-Dumeyer,
D., Lantigua, R., Ionita-Laza, I., Jones, D.P., Miller, G.W., and Mayeux, R. (2020). Differences in plasma metabolites
related to Alzheimer’s disease, APOE Y4 status, and ethnicity. Alzheimers Dement (N Y) 6. *equal contribution
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Figure 2.1: Alzheimer’s description of neuropsychological symptoms presented (Bondi, Edmonds,
and Salmon 2017)
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pathogenesis of Alzheimer’s disease (AD) is incomplete. Genetic and molecular mechanisms have
been proposed, but no single gene variant or molecular mechanism can fully explain the complexity
of this disorder. Genome-wide association studies have found more than 20 minor genetic loci to
be associated with the disease (Nikolac Perkovic and Pivac 2019). The APOE Y4 allele is a major
genetic risk factor with some estimates suggesting over 60% of persons with AD harbor at least
one allele. Apart from the APOE gene, age and chromosomal sex are also well-known risk factors
of the disease, with evidence that suggests an interaction between these three risk factors (Riedel,
Thompson, and Brinton 2016). While aging is the largest risk factor of the disease, evidence of
risk factors for dementias and AD show that lifestyle choices and the environment may modify
disease onset and alter the projected prevalence (Nichols et al. 2019; A Armstrong 2019; Scheltens
et al. 2016).
Given that the disease is accompanied by proteinopathies, pathways associated with main-
taining proteostasis have been studied to better understand pathogenesis of AD. The ubiquitin-
proteasome system (UPS) has received attention in recent years for its role in brain homeosta-
sis and neurodegeneration. Through proteomic analyses, changes in several proteins associated
with the UPS have been associated with AD (Harris, Jasem, and Licchesi 2020). Early stud-
ies reported ubiquitin-bound proteins in intra-neuronal neurofibrillary tangles and in extracellular
plaques. However, whether this is a result of dysregulation or active proteostasis remains unclear
(Mori, Kondo, and Ihara 1987; Cole and Timiras 1987; Harris, Jasem, and Licchesi 2020).
There is an emerging view that AD may be a metabolic neurodegenerative disease (Monte and
Wands 2008). AD has been associated with altered local and peripheral metabolism in in vitro
studies, animal models, and epidemiological studies. Studies have reported altered mitochondrial
function and energy metabolism in the brain of AD patients (Gibson, Sheu, and Blass 1998; Gibson
et al. 1999; Müller et al. 2010), some report these alterations even before AV aggregate formation
(Yao et al. 2010; Ye, Tai, and Zhang 2012). Indeed, animal studies have also reported that oxidative
stress, mitochondrial dysfunction and metabolic alterations are early events in AD pathogenesis
(Hauptmann et al. 2009; Reddy et al. 2004). Non-neuronal cells derived from AD patients also
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showed altered energy metabolism (Blass and Gibson 1992; Bosetti et al. 2002; Curti et al. 1997;
Swerdlow 2011), suggesting that these changes in metabolism are systemic and not restricted to
the central nervous system. It is interesting that Diabetes Mellitus, a metabolic disease associated
with mitochondrial dysfunction, is a risk factor for AD and brain insulin resistance is present in AD
patients (Arnold et al. 2018; Weise et al. 2018). Studies have suggested that glucose metabolism
becomes dysfunctional in AD (Weise et al. 2018). In a PET and MRI imaging study, brain glucose
and acetoacetate metabolism were altered in patients with AD (Croteau et al. 2018). Proteomic
analyses have reported that several glycolysis and mitochondrial TCA cycle enzymes are oxidized
in the AD brain (Butterfield and Boyd-Kimball 2018).
Mitochondrial dysfunction has been identified as an important factor involved in the early
pathology of neurodegenerative diseases, particularly AD. Mitochondrial dynamics and transport,
which is critical for proper energy production and synaptic function, has been reported to be al-
tered in AD (Flannery and Trushina 2019). Further, fibroblasts derived from patients of sporadic
AD showed impaired mitochondrial potential and abnormal redox potential. Metabolic pathways
associated with oxidative phosphorylation and energy production like nicotinamide adenine din-
ucleotide metabolism and the citric acid cycle were found to be reduced (Sonntag et al. 2017).
Indeed, studies have reported a “Warburg-like effect” in mild cases of AD, whereby neurons prefer
to produce energy through glycolysis and mitochondria appear quiescent, likely due to AV related
toxicity (Atlante et al. 2017).
APOE, a major genetic risk of AD, plays a role in lipid metabolism and homeostasis by medi-
ating the transport of lipids, fat-soluble vitamins and cholesterol between cells and tissues. Several
studies have reported altered lipid, cholesterol and phospholipid metabolism in AD (Zarrouk et
al. 2018; Liu and Zhang 2014). This association between lipid metabolism and AD offers avenues
for the search of new therapeutics (Lütjohann et al. 2000), mechanisms of disease pathogenesis
and progression (Lizard et al. 2012; Kou et al. 2011), and to identify biomarkers of preclinical AD
(Wurtman 2015; Fantini and Yahi 2010; Gonzales, Le, and Perry 2014).
Since no genetic loci can fully explain the disease, it is likely that genetic variants affect down-
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stream metabolic pathways. Finding systemic molecular changes between disease and healthy
states could identify biological mechanisms, potentially leading to early diagnosis and therapeutic
development and possibly successful interventions. Epidemiological, cross-sectional metabolomics
studies in AD cases have reported global metabolomic changes in choline and phospholipid metabolism
(Peña-Bautista et al. 2020; Niedzwiecki et al. 2020). Such metabolic profiles have also been used
to categorize sub-types of AD (Bredesen 2015).
Metabolomics analysis using the HRM method described in chapter 1 provides a deep molecu-
lar phenotyping that represents the underlying biochemical and physiological layer of the genome,
transcriptome and proteome. Metabolomics provides a precise and comprehensive analysis of phe-
notypic abnormalities in which the individual components are physiologically described. This snap
shot of the metabolic state of individuals is possible due to the advances in high-resolution mass
spectrometric platforms with high sensitivity and specificity that can strengthen the study at the
human population level. For this study, we conducted untargeted metabolomics profile analyses
in plasma to identify endogenous and exogenous metabolites associated with clinical AD, and to
identify differences by racial/ethnic group and APOE genotype.
2.2 Methods
2.2.1 Participants
The Washington Heights, Inwood Columbia Aging Project (WHICAP) has recruited a repre-
sentative community-based group of individuals aged 65 years and older through a collaborative
effort with the Centers for Medicare and Medicaid and through the use of marketing rolls. The
composition of the cohort reflects the community surrounding Columbia University Medical Cen-
ter and comprises of non-Hispanic whites (24%), African Americans (28%), Caribbean Hispanics
(48%) and 67% of the cohort are women. After obtaining informed consent, participants are inter-
viewed in either English or Spanish. During each assessment, participants received a standardized
neuropsychological test battery and medical interview. Blood was drawn, bar-coded, and brought
to the laboratory within two hours of collection for DNA extraction and storage of plasma and
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serum. All of the medical, neurological, psychiatric, and neuropsychological data collected were
reviewed at a consensus conference by clinicians who are experienced in the diagnosis of AD and
related dementias. Diagnosis of clinical AD was based on accepted criteria (McKhann et al. 2011).
For this investigation, fresh plasma was obtained, processed and frozen within two hours from
individuals who had been evaluated at least twice to ensure stability of the clinical diagnosis of AD
and the lack of dementia in healthy controls. These individuals were equally divided between the
three ethnic groups: African American, Caribbean Hispanic and non-Hispanic white and between
cases and controls (Table 2.1).
2.2.2 Metabolomics acquisition and analysis
We acquired metabolites by conducting untargeted metabolomics from the plasma in 119
cases and controls from the WHICAP cohort using a previously standardized method (Soltow
et al. 2013). Untargeted LC-based high-resolution mass spectrometry (LC-HRMS) allowed deep
phenotyping of the human metabolome, providing measures of metabolites in most Kyoto Ency-
clopedia of Genes and Genomes (KEGG) human metabolic pathways (Jones, Park, and Ziegler
2012). After chromatographic separation using methods previously described (Liu et al. 2016;
Walker et al. 2019), 10 `l of each sample was injected on each column (HILIC with positive
electrospray ionization (ESI) and C18 with negative ESI) three times, to obtain three technical
replicates per column. Data were processed through a computational pipeline that leverages open
source feature detection and peak alignment software, apLCMS (Yu et al. 2009b) and xMSanalyzer
(Uppal et al. 2013), to create a feature table with the mass-to-charge (m/z) ratio, retention time,
and the abundance of each ion in each sample. The feature table was used for statistical analyses
followed by untargeted pathway analysis using the software mummichog (Li and Le 2013). The
LC-HRMS platform detects over 1,500 chemical signals that arise from core nutrient metabolism,
lipids, the microbiome, diet-derived chemicals, pharmaceuticals and environmental contaminants,
as well as over 100,000 untargeted features (Johnson et al. 2020). For simplicity, we refer to the
mass spectral features as metabolites. Results described as annotations refer to level 4 and 5 con-
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Table 2.1: Demographic characteristics of cases and controls
Cases Controls
Caucasian (N) 19 20
Age (y) 89.2 93
Sex(% female) 79% 60%
APOEY4 allele frequency(%) 13.2% 2.5%
African American (N) 20 20
Age (y) 86.3 91.1
Sex(% female) 80% 90%
APOEY4 allele frequency(%) 30% 17.5%
Hispanic (N) 20 20
Age (y) 83.8 91.5
Sex(% female) 85% 90%
APOEY4 allele frequency(%) 15% 10%
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fidence of feature identification by criteria of Schymanski et al. (Schymanski et al. 2014). Results
described as identifications refer to level 1 confidence (accurate mass, retention time and MS/MS
fragmentation matching authentic standards).
2.2.3 Metabolomics data analysis
Raw metabolite intensities were corrected for batch effects using ComBat (Leek et al. 2012).
Metabolites missing in over 30% of the samples were excluded from further analysis. Metabolite
values missing or of low quality were imputed to half the value of the lowest level of detection
for each metabolite (Menni et al. 2013). Intensities were quantile normalized, log-transformed and
auto-scaled to normalize distributions (Berg et al. 2006).
Principal component analyses (PCA) of normalized values were used to estimate stratification
by ethnic/racial group, disease status and APOE Y4. Partial Least Squares Discriminant analysis
(PLS-DA) implemented in the mixOmics (Rohart et al. 2017) package was used to conduct super-
vised dimension reduction analysis to obtain a linear combination of the features that correlated
with variability by ethnic/racial group, disease status and APOE Y4 in the metabolomics data.
We tested association of individual metabolites with AD adjusting for age, sex, APOE-Y4 and
ethnic/racial group. In addition, we tested the association of these metabolites with AD inde-
pendently in each ethnic/racial group (defined by PCAs and ancestry analysis of GWAS data) to
identify both ancestry specific and population-based metabolomics signatures in AD. Then, we
tested association of APOE Y4 with metabolite intensities adjusting for age and sex. For associa-
tion testing of independent metabolites, we declared nominal significance at p < 0.05. Nominally
significant metabolites were subsequently tested for pathway enrichment. Pathways enriched for
metabolites associated with traits of interest were detected using module-enrichment analysis im-
plemented in mummichog (Li and Le 2013). Statistical significance of enriched pathways was




Untargeted metabolomics profiles were completed in 119 individuals that included 40 African
Americans, 40 Caribbean Hispanics and 39 non-Hispanic whites from the WHICAP cohort. Using
the HILIC column with positive electrospray ionization (ESI), we identified over 9,700 features,
of which 5,929 were putatively annotated using xMSannotator. The features did not show batch
related variation and a total of 6375 features were present in at least 70% of the samples studied,
of which 1,704 metabolites were annotated with xMSannotator confidence level 2 or 3. Using the
C18 column with negative ESI, we measured over 6,700 features, of which 3759 were present in
at least 70% of the samples.
2.3.1 Metabolomic profiles of Alzheimer’s disease
We compared metabolites between AD and controls adjusted for age, sex and ethnic/racial
group and found several metabolic features nominally associated with AD (nominal p < 0.05)
measured on both columns (figure 2.2A, Table 2.3) as well as unique metabolic profiles (Table
2.2).
While none of the individual metabolites reached experiment-wide significance after correct-
ing for multiple testing, we identified several metabolites annotated with a confidence level 2 by
xMSannotator that were associated with AD at p < 0.001 (Table 2.2). In particular, we identi-
fied benzyl chloride, various adducts of benzenes and toluenes, omega 3 fatty acids, ceramide and
carnitines that are associated with Alzheimer’s disease.
In addition, features from the HILIC positive data indicated that altered polyunsaturated fatty
acid biosynthesis, alanine, aspartate, glutamate, glycerophospholipid and sphingolipid metabolism
(Figure 2.2C) were also associated with AD metabolome-wide. Data from the C18 negative
column implicated altered glycolysis and gluconeogenesis, pyruvate and alanine and aspartate
metabolism in cases versus controls of AD. Individual metabolites that contributed to enrichment
of these pathways are described in Supplementary Material.
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Figure 2.2: Metabolome wide association study in cases and controls of AD. A. A metabolome
wide association study (MWAS) found 382 features altered in cases and controls at nominal signif-
icance of p < 0.05 In red: features lower in cases, in green features higher in cases. B. A PLS-DA
shows metabolomic patterns different between cases and controls (unadjusted for age and sex vari-
ables). C. Pathway analysis using mummichog shows most probable metabolic pathways altered
between cases and controls. We tested enrichment of pathways among metabolites that were nom-
inally significant in association with AD (p<0.05) in models unadjusted and adjusted for APOE
respectively. Displayed pathways are enriched at p < 0.05, corrected for multiple testing.
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Table 2.2: Individual metabolites associated with AD status and annotated with a confidence
score>2
m/z time V p-value HMDB ID Theoretical
m/z
X ppm Name
127.03 53.80 -0.82 5.23E-04 HMDB59882 127.03 7.08 Benzyl chloride









594.58 68.20 -0.72 1.04E-03 HMDB04951 594.58 0.62 Ceramide (d18:120:0)
291.20 41.60 0.72 1.12E-03 HMDB31098 291.20 1.27 octadecatetraenoic acid




2.3.2 Metabolomics differences by racial/ethnic groups
Within each ethnic/racial group, we found that African Americans with AD had altered glycol-
ysis and amino acid metabolism as well as polyunsaturated fatty acid metabolism. Non-Hispanic
whites with AD had altered amino acid, fatty acid, and glycosphingolipid metabolism, and Caribbean
Hispanic cases had altered amino acid metabolism (Figure 2.3). Restricting the analysis to con-
trols, we determined underlying metabolic differences that existed in participants based on their
ethnic/racial group was not driven by the presence of disease (Figure 2.4A, Table 2.3).
Compared with Caribbean Hispanics and non-Hispanic whites, partial least squares discrim-
inant analysis (PLS-DA) suggested features in African Americans clustered differently (Figure
2.5), including altered amino acid metabolic pathways such as arginine and proline metabolism,
asparate and asparagine metabolism, and glycine, serine, alanine and threonine metabolism. Sat-
urated fatty acid beta oxidation was also identified based on variable importance in the projection
(VIP) scores from the PLS-DA (Figure 2.5).
2.3.3 Metabolomics profiles associated wtih APOE genotype
We also investigated metabolic differences driven by APOE Y4. PLS-DA identified near com-
plete separation between APOE Y4 carriers and non-carriers (Table 2.5). In contrast to pathways
identified by AD diagnosis, the presence of APOE Y4 was associated with changes in arachi-
donic acid metabolism, driven by features with putative matches to octadecatrienoic acid and
icosatrienoic acid (Figure 2.6 A and B), changes in the hexose phosphorylation pathway, and in
methionine and cysteine metabolism. After adjusting for APOE Y4, the pathways associated with
AD were largely the same (Figure 2.1C).
2.4 Discussion
We compared the untargeted metabolomic profile of patients with AD and healthy controls,
equally divided between African Americans, Caribbean Hispanics and non-Hispanic whites. The
27
Figure 2.3: Racial/Ethnic differences. A bubble plot that shows pathways altered in controls of the
three ethnic groups. Size of bubbles is proportional to overlap size of pathway.
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Figure 2.4: A. A PLS-DA with all ethnic groups shows a African Americans differ from the Cau-
casian and Hispanic individuals. B. A PLS-DA the shows differences when comparing AAs with
all others.
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Figure 2.5: A. A PLS-DA with all ethnic groups shows a African Americans differ from the Cau-
casian and Hispanic individuals. B. A PLS-DA the shows differences when comparing AAs with
all others. C. Pathways analysis of features that are significantly different in cases and controls of
African Americans.
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Figure 2.6: APOE status and metabolic differences. A. MWAS shows features associated with
APOE status. B. PLS-DA showing separation between APOE Y4 carriers and non-carriers. C.
Metabolic pathways enriched in metabolites that are associated with APOE Y4 status at a nominal
significance of p < 0.05.
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goal of this investigation was to identify metabolites associated with disease while adjusting for
the strongest genetic risk factor, APOE and ethnic/racial group. Therefore, we used a simple case-
control design equally stratified by ethnic/racial group.
We found significant differences comparing exogenous and endogenous metabolites in patients
with AD and healthy controls. Similar differences were observed in a comparison of metabolic pro-
filing in brain tissue from the middle frontal and inferior temporal gyri in healthy controls, patients
with AD or mild cognitive impairment (MCI) in the Baltimore Longitudinal Study (Snowden et
al. 2017). An untargeted approach has also been used to correctly classify patients with mild cog-
nitive impairment or AD when compared with controls with 97.7% accuracy (Graham et al. 2015).
However, metabolite analyses identified 22 putative biochemical pathways, including interlinked
areas of metabolism (polyamine metabolism and L-arginine metabolism).
In this report, we identified several metabolites associated with AD that were altered in the fatty
acid biosynthesis pathway. Interestingly, dysregulation of unsaturated fatty acid metabolism was
previously reported in brain tissue from patients with AD compared to healthy controls (Snowden
et al. 2017). The disruption in polyunsaturated fatty acid biosynthesis may have several down-
stream effects: inflammation, oxidative stress, cell maintenance or cell death. Several amino acid
metabolism related pathways were also enriched among metabolites that were associated with risk
of AD. Lower levels of glutamate and aspartate, and higher levels of glutamine have been observed
in the temporal cortex, in postmortem samples from patients with AD (Gueli and Taibi 2013). A
different cohort also showed elevations in plasma levels of glutamine in AD patients (Niedzwiecki
et al. 2019a). We identified metabolites involved in dynorphin metabolism associated with AD,
consistent with previous studies in postmortem samples from patients (Yakovleva et al. 2007). Ex-
pression of dynorphin, an endogenous opioid peptide, increases with age and has been associated
with cognitive impairment in rodent models (Ménard et al. 2014).
We found ceramide to be significantly associated with AD , and it has been suggested that ce-
ramide promotes neuronal apoptosis, AV accumulation (Jazvinšćak Jembrek, Hof, and Šimić 2015)
and has been seen at increased levels in patients with AD and co-morbid conditions (Filippov et
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al. 2012). In addition, lower levels of plasma acylcarnitine were found in AD patients compared
to controls. Plasma acylcarnitines predict altered fatty acid beta-oxidation, and ketogenesis and
have been reported to be depressed in AD patients (Ciavardelli et al. 2016). Metabolic features
also differed significantly in the three ethnic/racial groups, especially among African Americans,
despite the individuals being similar in age and residing in the same geographical location. Very
few studies have investigated overall metabolic differences by ethnicity/race. Investigators from
the Women Health Initiative cohort identified significant differences in metabolite profiles between
African Americas and individuals of European ancestry (Hu Jie et al. 2019). Similar differences in
amino acid and lipid metabolism were observed in a metabolic profiling study of serum metabolites
in African American and European American patients with bladder cancer (Vantaku et al. 2019).
Thus, genetic and metabolic factors could help to explain ethnic/racial and racial disparities in the
risk factors associated with AD. Similar pathways emerge when we asses difference by AD or eth-
nic/racial group suggesting that metabolome profiling from plasma could be used to identify racial
differences in disease. Differences between APOE Y4 carriers and non-carriers were apparent and
remained when analyses were restricted to healthy individuals from all three ethnic/racial groups.
Interestingly, metabolites associated with AD were different from those associated with APOE Y4.
Hexose phosphorylation and arachidonic acid metabolism pathways were most enriched amongst
metabolites that were associated with APOE Y4. APOE Y4 carriers converting to MCI/AD had
higher arachidonic acid (AA)/docosahexaenoic acid (DHA) ratios in phospholipids compared to
cognitively normal Y4 and non-Y4 carriers (Abdullah et al. 2017). Alterations in plasma arachi-
donic acid were observed in the brains of Y4 carrier mice compared to non-carriers (Abdullah et
al. 2017).
Taken together these results suggest that understanding metabolic heterogeneity in AD patho-
genesis may enable identification of biological mechanisms for specific subgroups with the disease.
Namely, those carrying an APOE Y4 allele and among those of African or Hispanic ancestry. This
study demonstrates the ability of untargeted metabolomics to reveal biochemical differences in
plasma based on ethnicity/race, the presence of APOE Y4, and AD, thus informing study design
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for optimal power of discovery in larger studies.
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Table 2.3: PLS-DA performance in separating three ethnic groups using all 119 individuals (60
AD cases and 59 controls)
Component 1
AUC p-value
AFRICAN AMERICAN vs Other(s) 0.9275 2.95E-14
EUROPEAN vs Other(s) 0.5478 3.99E-01
HISPANIC vs Other(s) 0.8804 1.36E-11
Component 2
AUC p-value
AFRICAN AMERICAN vs Other(s) 0.9816 0.00E+00
EUROPEAN vs Other(s) 0.6904 7.71E-04
HISPANIC vs Other(s) 0.8994 1.25E-12
Component 3
AUC p-value
AFRICAN AMERICAN vs Other(s) 0.9972 0.00E+00
EUROPEAN vs Other(s) 0.9804 0.00E+00
HISPANIC vs Other(s) 0.9601 2.22E-16
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Table 2.4: PLS-DA performance in separating 60 AD cases from 59 age-matched healthy controls
Component 1
AUC p-value
AD vs HEALTHY 0.8842 4.89E-13
Component 2
AUC p-value
AD vs HEALTHY 0.9907 0
Component 3
AUC p-value
AD vs HEALTHY 1 0
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Table 2.5: PLS-DA performance in separating APOE Y4 carriers from non-carriers
Component 1
AUC p-value
E33 vs E4s 0.9195 2.56E-12
Component 2
AUC p-value
E33 vs E4s 0.995 2.22E-16
Component 3
AUC p-value
E33 vs E4s 1 0
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Chapter 3: DDT exacerbates tau protein toxicity in Caenorhabditis elegans
3.1 Introduction
1In 2014, 5 million people in the US were living with Alzheimer’s disease (AD). By 2060,
this number is projected to grow to 13.9 million (Matthews et al. 2019). Clinically, AD manifests
as dementia, a progressive deterioration of memory and cognitive function (Van Cauwenberghe,
Van Broeckhoven, and Sleegers 2016). Pathologically, it is characterized by severe neuronal loss
reported to begin in the medial temporal lobe, which includes parts of the brain responsible for
cognition and memory, the hippocampus and entorhinal cortex. As the disease progresses, areas in
the cerebral cortex are destroyed including the prefrontal cortex, which is responsible for reasoning
and social behavior. In the final stages of the disease, brain atrophy is widespread (Jellinger and
Bancher 1998; Yilmazer-Hanke and Hanke 1999). In these brain regions, postmortem analyses
show aggregation of amyloid-V (AV) in extracellular senile plaques, and formation of intraneuronal
neurofibrillary tangles consisting of hyperphosphorylated tau protein. While aging is the largest
risk factor of the disease, evidence of risk factors for dementias show that lifestyle choices and the
environment may modify disease onset and alter the projected prevalence (Nichols et al. 2019).
The role of the environment in the onset of AD has a controversial history (DeKosky and Gandy
2014) but recent studies provide evidence of environmental chemical exposures affecting disease
risk. In a cross-sectional, case-control study, Richardson and others (2014) found that cases of
AD had higher levels of the pesticide DDT, and its metabolite DDE, in their serum (Richardson
et al. 2014).
Dichlorodiphenyltrichloroethane (DDT; (1,1,1-tricholoro-2,2-bis(p-chloro-phenyl) ethane)) is
1Kalia, V., Bradner, J., Niedzwiecki, M., Lau, F., Bucher, M., Manz, K., Coates Fuentes, Z., Pennell, K., Walker,
D.I., Picard, M., Hu, W., Jones D.P., Miller, G.W. Cross-species metabolomic analysis of DDT and Alzheimer’s
disease-associated tau toxicity. In preparation.
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a highly persistent, synthetic organochlorine pesticide used for pest control in agricultural settings
and to control vectors that can cause diseases like malaria and typhus. It was widely used in the
USA from 1939 to 1972, until its use was banned by the US Environmental Protection Agency (Tu-
rusov, Rakitsky, and Tomatis 2002). The use of DDT in some other countries has declined since the
Stockholm convention was enacted in 2004, which aimed to protect human health and the environ-
ment by eliminating the use of 12 persistent organic pollutants globally, including DDT (Fiedler
2008). Despite its regulation, DDT and its metabolites remain persistent and can be detected in
the blood of most of the US population (National Report on Human Exposure to Environmental
Chemicals | CDC 2020). DDT shows adverse effects on BMI and growth, which is thought to be
through its endocrine disrupting effects (Tang-Péronard et al. 2011). There is evidence that DDT
is a hepatic carcinogen (Harada et al. 2003) and is associated with chronic kidney disease (Ghosh
et al. 2017). DDT is thought to exert neurological effects by disrupting ion fluxes (Bloomquist
1996). Low dose exposure to DDT has been associated with altered DNA methylation in the
hypothalamus of young male mice (Shutoh et al. 2009).
Caenorhabtidis elegans is a non-parasitic nematode that has been gaining popularity as an in
vitro model in toxicity texting. Toxicity ranking of several toxicants in C. elegans is predictive of
rat LD50 values for those toxicants (Hunt 2017).The effect of several toxicants have been studied
in C. elegans. The toxic effects of endocrine disrupting chemicals (Allard et al. 2013), neurode-
velopmental toxicants (Hunt et al. 2018), neurotoxicants (Avila, Helmcke, and Aschner 2012),
nanoparticles (Wu et al. 2019), metals (Lawes et al. 2020), and plasticizers (Camacho et al. 2018)
have been studied in the model. Furthermore, the National Toxicology Program has been using
the model to create high-throughput toxicity assays (Boyd et al. 2016). The model is low cost and
requires standard techniques for maintenance in a lab. Worms can grow up to 1mm long and feed
on bacteria and fungi. They have a short life cycle, about 3 days, and each hermaphrodite has the
capacity to produce 300 progeny. Several aspects of biology were discovered and are studied in
C. elegans including apoptosis, RNAi, and miRNA. Furthermore, C. elegans are the first complex
organism to have their genome sequenced (C. elegans Sequencing Consortium 1998) which has
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allowed researchers to a large library of genetic mutant strains. The long history of its use in biol-
ogy makes it valuable for biological insight (Corsi, Wightman, and Chalfie 2015; Brenner 1974).
Given the genetic knowledge and its tractability there are several mutants and transgenic strains
available to study gene x environment interactions. Of great importance is also the fact that several
genes and pathways are conserved between C. elegans and humans (Kaletta and Hengartner 2006).
To the best of our knowledge, there has not been a comprehensive study of the interaction
between underlying genetic susceptibility to Alzheimer’s disease or dementia and exposure to low
levels of DDT. Here, we use transgenic strains of C. elegans that express human tau protein and a
mutant pro-aggregating fragment of tau protein associated with frontotemporal dementia (Fatouros
et al. 2012) to study the effect of concomitant exposure to DDT on growth, behavior, metabolism,
learning, and survival endpoints.
3.2 Methods
3.2.1 Worm growth and maintenance
Standard methods of culture including the use of normal or high growth media (NGM/ HGM)
plates, culture temperatures of 20 ◦C and the OP50 E. coli strain as a food source were followed
as described (Brenner 1974). Deviations in this practice are mentioned in conjunction with the
relevant assay. C. elegans strains were provided by the CGC, which is funded by NIH Office of
Research Infrastructure Programs (P40 OD010440). These include the wild type N2 Bristol strain,
BR5271 (byIs162 [Prab-3::F3(delta)K280 I277P I380P + Pmyo-2::mCherry]; referred to as the
“non-agg” strain), BR5270 (byIs161 [Prab-3::F3(delta)K280 + Pmyo-2::mCherry]; referred to as
the “agg” strain), and the TK22 (mev-1) strain.
3.2.2 Exposure to DDT
Worms were exposed to the pesticide p,p’-DDT (Fisher Scientific) or the solvent control,
DMSO (Fisher Scientific), on NGM plates. DDT exposure plates were created using methods
described by Hunt and others (Hunt et al., 2011). Briefly a 20 mM stock of DDT, made by dissolv-
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ing in 100% DMSO, was diluted to 150`M with sterile water and then applied on to NGM plates
spotted with OP50 E. coli to obtain the appropriate final concentration of DDT on the plate. The
solvent control plates were created following the same dilution but without DDT to achieve a final
concentration of 0.015% DMSO. DDT was allowed to diffuse and the plates were allowed to equi-
librate for 2 hours before worms were introduced. All worms were exposed to a final concentration
of 3 `M DDT, unless otherwise stated.
3.2.3 Worm growth, collection, and processing for GC-MS analysis of DDT and metabolites
A synchronized population of wildtype worms, created using hypochlorite treatment, were
grown on 10cm NGM plates with 0.3, 3, or 30 `M DDT, and the solvent control. The non-
aggregating and aggregating worms were similarly synchronized and exposed to 3 `M DDT or
the solvent control. All strains were collected after 72 hours of exposure, at the young adult stage.
They were washed in M9 4x and sorted into aliquots of 1000-1200 worms using the COPAS FP-
250. Once created, the volume of M9 in each aliquot was reduced to 100 `l and each sample was
snap frozen in liquid nitrogen. To extract DDT and its metabolites, the worm cuticle was disrupted
by bead beating and the samples were analyzed for levels of p,p’-DDT and its metabolite p,p’-DDE
at the Pennell lab in Brown University.
Chemicals. Certified reference standards for GC-HRMS quantification were purchased from
Accustandard, including o,p’ DDT, p,p’-DDT, o,p’-DDE, p,p’-DDE, 13C12 labeled p,p’-DDE, D8
labeled p,p’-DDT phenanthrene D-10, and chrysene D-12. Acetone (99.8%, HPLC grade), n-
hexane (≥99%), and dichloromethane (99.8%, HPLC grade) were purchased from Fisher Scien-
tific.
Sample extraction and preparation. High resolution gas chromatography – mass spectrom-
etry (GC-HRMS) was used to measured worm tissue concentrations of o,p’-DDT, p,p’-DDT, o,p’-
DDE, and p,p’-DDE using methods previously described (Elmore et al. 2020). Prior to extraction,
each sample was spiked with 10 `L of a solution containing 13C12 labeled p,p’-DDE and D8 labeled
p,p’-DDT as internal standards to assess recovery. Each sample was extracted using a QuEChERS-
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based (Quick, Easy, Cheap, Effective, Rugged, Safe) extraction. The samples were first vortex
mixed in centrifuge tubes with 1 mL 1:1:1 hexane:acetone:dichloromethane and sonicated for 30
minutes. The entire sample and the supernatant were transferred to a micro-QuEChERS tube con-
taining 150 g MgSO4 and 50 mg C18 (United Chemical Technologies, Bristol, PA), vortexed for
30 seconds, and centrifuged for 5 minutes at 3,000 rpm. The supernatant was transfer to a glass
GC vial for collection. The QuECHER extaction was repeated 2 more times (the sample cen-
trifuge tube was rinsed with the 0.5 mL solvent mixture, transferred to the QuEChERS tube, and
collected in the collection vial). The final 2 mL extract was evaporated to 150 `L under nitro-
gen (Organomation 30 position Multivap Nitrogen Evaporator), transferred to a low-volume (300
`L) GC vial, and spiked with phenanthrene-D10 and chrysene-D12 as internal standards to ensure
injection consistency during GC-MS analysis.
GC-HRMS Analysis. Extracts were analyzed on a GC Q-Exactive Orbitrap MS (Thermo Sci-
entific) equipped with a Thermo Trace 1300 gas chromatograph and TriPlus RSH Autosampler. 3
`L was injected into a 290◦C split/splitless inlet operated in split-less mode. The analytes were
separated on a Restek Rxi-35Sil MS column (30 m x 0.25 mm inner diameter x 0.25 `m film thick-
ness) with Helium (99.999% purity) as the carrier gas (1 mL/min). The oven temperature ramp
began at 50◦C for 0.5 min, increased 30◦C/min to 200◦C and held for 1 minute, and 10◦C/min
to 300◦C and held for 1 min. The transfer line was maintained at 300◦C and the EI source tem-
perature at 250◦C. The MS was operated in full scan mode, with a scan range of 50 to 750 m/z.
The total run time was 17.5 minutes and data were collected between 4 and 16 minutes. The most
abundant peak in the mass spectrum was used to quantify each analyte and identity was confirmed
using the ratio of two confirming ions and retention times (Table 3.1). Quantification was per-
formed using a ten-point calibration curve prepared by serial dilution of calibration standards in
hexane (0.007 to 40 `g/L). The limit of detection (LOD) for each target analyte was determined
from seven injections of calibration standards and calculated using the following equation:
!$ = B ∗ C (35 , 1 − U)
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where B is the standard deviation of the 7 injections, C is the student’s t-value, 35 is the degrees
freedom, and U is the level of significance (for = = 7 and U = 0.01, C = 3.14).
3.2.4 Growth determined through size measured on COPAS Biosorter
The COPAS Flow Pilot (FP) 250 is a tool used for high-throughput manipulation of C. elegans.
The instrument is similar to a fluorescence-activated cell sorter (FACS) but made specifically to
measure fluorescence along the length of a worm. For each worm that passes through the flow
cell, the COPAS FP-250 determines its time-of-flight (TOF), which represents the length of the
worm passing through the flow cell, and the extinction, which represents the optical density or
thickness of the worm passing through the flow cell. Objects are analyzed and sorted using size,
optical density and up to three channels of fluorescence. After hypochlorite synchronization, eggs
were allowed to hatch and develop on 10cm NGM plates with 3 `M DDT and the solvent control.
Worms were sorted through the COPAS FP 250 to measure TOF and extinction 46-50 hours after
synchronization (around the L4 stage) and at 70-72 hours post synchronization (around young
adults). Measures of TOF and extinction were compared across the strains and treatment groups
and the two time points.
3.2.5 Swim behavior
The celeST software package was used as described to determine aspects of swim behavior
for the different strains exposed to DDT and the solvent control (Restif et al. 2014). Briefly, 3-4
worms at the young adult stage were placed in 60 `l of M9 on a glass slide. Recordings of swim
behavior were made as a series of jpeg images using a chameleon 3 camera ((FLIR) Wilsonville,
OR) for 30s at a frame rate of 18 f/s. Data are collected from four-five trials representing different
experiments, with a total of 50 -100 worms recorded per group.
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o,p’-DDE 11.13 245.9999 247.9968 317.9345 0.016
o,p’-DDT 12.80 235.0076 165.0699 237.0047 0.010
p,p’-DDE 11.70 245.9999 247.9968 317.9345 0.029
p,p’-DDT 13.32 235.0076 165.0699 237.0047 0.029
4,4’-DDE (13C12) 11.70 260.0370 188.1021 258.0400
4,4’-DDT (D8) 13.27 243.0576 173.1200 245.0549
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3.2.6 Seahorse XFe96 extracellular flux analysis
The three strains exposed to DDT or solvent control were collected at the young adult stage and
washed in M9 4x for analysis using the Seahorse XFe96 extracellular flux analyzer as described
by Koopman and others (Koopman et al. 2016). Briefly, 3-30 worms in M9 buffer were plated
into the wells of a utility plate and the volume of M9 in each well was made up to 200 `l. M9
buffer without any worms was used as the blank for background correction. Baseline respiration
was measured, followed by injection of FCCP (10 `M, final concentration) to elicit maximal res-
piration, followed by sodium azide (40 mM, final concentration) to account for non-mitochondrial
respiration. Data are normalized to the number of worms in each well to determine the picomole
of oxygen consumed per minute per worm. Basal respiration was determined as the difference
between non-mitochondrial respiration and the average oxygen consumption rate at measurements
2 through 5; maximal respiration was determined as the difference between non-mitochondrial res-
piration and the average oxygen consumption rate measured after the FCCP injection; and spare
respiratory capacity was measured as the difference between basal respiration and maximal respi-
ration.
3.2.7 High-resolution metabolomics
A synchronized population of worm eggs were allowed to hatch and grow on the DDT exposure
or solvent control NGM plates until the L4 stage. Worms were then washed 4x using M9 and
sorted into four-six replicates using a COPAS FP-250. The final volume was reduced to 100 `l
and each sample was snap frozen in liquid nitrogen and stored at -80◦C until needed for high-
resolution metabolomics processing. The extraction of metabolites for analysis has been described
previously (Mor et al. 2020). Briefly, metabolites were extracted using acetonitrile, added in a 2:1
ratio. Bead-beating was used to disrupt the worm cuticle and improve extraction. A spatula-full
(∼10 beads) of zirconium oxide beads (0.5 mm, Yttria stabilized) from Next Advance (Troy, NY)
were added to each tube. Each sample was placed in the bead beater at 6.5 m/s for 30 seconds,
allowed to equilibrate on ice for one minute, and placed in the beater for another 30 seconds, at
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the same speed. All processing was performed on ice or in a cold room when necessary. The
supernatant was diluted 1:1 in HPLC-grade water and analyzed in the Walker lab at the Icahn
School of Medicine at Mount Sinai. Untargeted high-resolution mass spectrometry was run using a
HILIC column (positive and negative ESI mode) and C18 column (positive and negative ESI mode)
using chromatographic methods previously described (Soltow et al. 2013). Mass spectral data was
generated on an orbitrap mass spectrometer in full scan mode, scanning for mass range 85 to 1250
Da. Data were extracted using the R packages apLCMS (Yu et al. 2009a) and xMSanalyzer (Uppal
et al. 2013). Annotations were made using xMSannotator (Uppal et al., 2017) with the WormJam
consensus C. elegans metabolic map as the reference (Witting et al. 2018). (See appendix B for
more detail)
3.2.8 Metabolome wide association analysis
The four feature tables generated from data acquisition were treated similarly. First, the inten-
sity of a feature in the samples was compared to its intensity in the medium blank (M9 buffer).
If the intensity was at least more than 1.5 times the intensity in the blank samples in all samples,
it was retained for downstream analysis. Second, if a feature was missing from less 50% of the
samples, it was imputed with half the value of the minimum intensity measured. Features missing
from more than 50% of the samples were removed from downstream analysis. Third, the filtered
and imputed feature table was imported into MetaboAnalyst (Pang et al., 2020) and normalized
by generalized log transformation. The normalized feature table was used to determine: 1. The
metabolomic profile of DDT exposure in wildtype worms, 2. the metabolomic profile of DDT
exposure in the agg worms, 3. The Metabolomic profile associated with the agg worms by com-
paring features from the agg and non-agg worms exposed to the vehicle control. For all analyses,
the intensity of features were compared across the two groups using a t-test. The features of sig-
nificance were tested for pathway enrichment using the mummichog algorithm (Li et al., 2013) on
MetaboAnalyst using the C. elegans KEGG reference map.
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3.2.9 Congo red stain
Fifty worms from each treatment group were transferred to a 5 `L drop of H2O on a microscope
slide coated with poly-l-lysine. The animals were freeze fractured as previously described (Duerr
2013). Worms were stained with congo red dye following the method described by Wang and
others (Wang et al. 2018). Briefly, the slides with fractured worms were dried using a heating
block set to 55◦C for about 30 seconds. A 25 `l drop of 0.5% Congo red in 50% ethanol/10 mM
Tris buffer (ph 7.5) was added and the slides were incubated for 3 hours in a humid chamber at
20 ◦C. The stain was then removed by immersion in water and worms were destained using 25 `l
of a destaining solution (0.5% potassium hydroxide and 80% ethanol). After about 40 seconds,
the slide was reimmersed in water and the destain repeated for about 10 seconds, followed by
the final water immersion. The slides were dried and sealed using 5 `l of mounting medium and
a coverslip, and sealed using nailpolish. The slides were observed using a Leica DMi8 (Leica;
Wetzlar, Germany) inverted epifluorescent microscope at 400x magnification (excitation at: 540
nm, emission at: 477 nm).
3.2.10 Short-term associative memory assay
The short-term associative learning assay was carried out as previously described (Kauffman
et al. 2011) with some modifications. The assay relies on an associative memory paradigm where
worms are trained by pairing the presence of food with the odor of 10% butanone. Briefly, worms
were hypochlorite synced and allowed to grow on DDT or solvent control plates for about 72
hours, until they reached the young adult stage. Worms were collected off plates and washed 3x.
After the last wash, the naive attraction toward butanone was assessed. Worms were then starved
for an hour, after which the conditioned training was performed to pair the odor with the presence
of food. The attraction toward butanone was determined just after conditioning, representing their
ability to learn and form an associative memory. To count the number of worms attracted to the
butanone spot or the control (95% ethanol) spot, images of the entire assay plates were taken on
a Basler GigE camera, and the images were analyzed using a MATLAB algorithm created by the
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Murphy lab (Kauffman et al. 2011).
3.2.11 Lifespan analysis
Wildtype worms and the transgenic strains were exposed to DDT or the solvent control until the
young adult stage, around 72 hours. After exposure, worms were collected off plates and washed
4 times. The number of worms were counted and 25-35 worms were placed on standard 6 cm
NGM plates to create 4 replicates per strain tested. Adult worms were counted and transferred
everyday onto new 6 cm NGM plates until they stopped producing progeny ( adult day 6). At this
point, worms were transferred onto 6 cm NGM plates with nystatin and ampicillin. Worms were
then counted every other day and scored as dead if they did not respond to the gentle touch of a
platinum wire. A worm was censored from the plate if it was missing, showed internal hatching, or
was damaged during transfer. Worms were followed until they were all dead. Data was analyzed
using Kaplan Meier survival calculations and the log-rank test.
3.2.12 Statistical analysis
Tests for significance were determined through ANOVA and post-hoc Tukey’s HSD test, unless
stated otherwise. All data were analyzed in R (version 4.0.2) unless otherwise stated.
3.3 Results
3.3.1 DDT is absorbed and metabolized in C. elegans
The C. elegans cuticle is known to be an effective barrier against absorption of toxicants (Hunt
2017). The nematode is known to possess CYP 450 enzymes, although their repertoire is not as
extensive as in mammals (Harlow et al. 2018). We determined whether worms can take up DDT
and metabolize it by measuring the levels of p,p’-DDT, p,p’-DDE, p,p’-DDD, o,p’-DDT, o,p’-DDE
and o,p’-DDD in worms using GC-MS based targeted analysis. In wildtype worms, exposure to
0.3, 3, and 30 `M DDT led to internal levels of 0.27, 0.49 and 1.3 picogram of p,p’-DDT in
each worm, respectively (Figure 3.1). The levels of p,p’-DDE were about 5-10 times lower than
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p,p’-DDT in the wildtype, agg and non-agg strains exposed to 3`M DDT (Table 3.1). All other
metabolites of p,p’-DDT were also detectable and measured in the control and transgenic strain
(Figure 3.9).
3.3.2 Expression of aggregating tau protein and exposure to DDT restricts growth, measured
through size.
Assessment of TOF (length) and extinction (optical density) at 46-50 hours post synchroniza-
tion ( larval stage 4) revealed that the aggregating tau strain were smaller and with lower density
compared to the non-aggregating and wildtype worms. Exposure to DDT reduced the size and den-
sity in all strains assessed (Figure 3.2 A and B). Measurement at 70-72 hours post synchronization
(young adulthood) showed that both tau transgenic strains are smaller than wildtype worms, with
the aggregating tau strains more severely affected. Exposure to DDT reduced the size of all strains
in a graded manner, with the aggregating tau strains exposed to DDT being the smallest (Figure
3.2 C and D).
3.3.3 Aggregating tau protein interferes with swim behavior and DDT interacts with tau protein
to increase time spent curling.
The aggregating tau transgenic strain showed differences in wave initiation rate and travel
speed, compared to the wildtype worms (Figure 3.3 A and B). Exposure to DDT in the aggregating
strain increased the amount of time the worms spent curling when swimming (Figure 3.3 C). The
aggregating tau strain showed a lower activity index (Figure 3.3 D), and a difference in time spent
reversing and brushstroke (Figure 3.10) compared to wildtype worms. DDT did not change any
swim behavior in the wildtype or non-aggregating tau strain.
3.3.4 Aggregating tau protein and DDT inhibit mitochondrial respiration.
Wildtype worms and the non-aggregating tau strain showed similar oxygen consumption pro-
files. The aggregating tau strain showed reduced levels of basal, maximal, spare, and non-mitochondrial
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Figure 3.1: Absorption and metabolism of DDT. In wildtype worms, exposure to increasing levels
of DDT shows increasing internal levels of p,p’-DDT and its metabolite, p,p’-DDE (A). Internal
levels of p,p’-DDT and p,p’-DDE in all strains exposed to 3`M DDT (B). All three strains exposed
to 3 `M DDT were collected in triplicate and the mean level of each the parent and its metabolite
was listed with the standard deviation in parentheses.
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Figure 3.2: Growth determined through size measured on COPAS Biosorter. The aggregat-
ing strain is smaller in size at the larval stage 4 and in young adulthood compared to the non-
aggregating ad wildtype strain. Exposure to DDT restricted the growth of all strains at both stages
measured. *** Tukey HSD adjusted p < 0.0001.
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Figure 3.3: Aggregating tau and DDT affect swimming behavior. The aggregating tau strain shows
altered wave initiation rate (A) and travel speed (B) compared to the wildtype N2 worm. The
aggregating tau strain exposed to DDT spends more time curling while swimming compared to
when not exposed (C). The overall activity index of the aggregating tau strain is reduced compared
to the wildtype N2 strain. Each bar represents the mean measure taken from four-five different
trials with 50-100 worms per group. The error bars represent the standard error of the mean. *
Tukey HSD adjusted p < 0.05.
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respiration when compared to the non-aggregating tau strain (Figure 3.4. B - E). Exposure to 3`M
DDT in the N2 and non-aggregating tau strain reduced the overall OCR profile (Figure 3.4 A) and
reduced all four measures of respiration (Figure 3.4 B - E). Exposure to DDT in the aggregating
strain significantly reduced basal respiration (Figure 3.4 B). While the other measures of respira-
tion were also reduced due to DDT exposure, none of them were significantly different (Figure 3.4
C – E) from the solvent control treatment.
3.3.5 DDT causes widespread alterations in the whole-worm metabolome
A biplot of principal component (PC) 1 against PC2 shows that the wildtype and non-agg strain
cluster together while the strains exposed to DDT were separated from the unexposed wildtype
and non-agg strain along PC1 (Figure 3.5 B). All strain exposed to DDT showed lower levels
of several features measured on the HILIC column under positive ionization (Figure 3.5 A) and
negative ionization (Figure 3.11) as well as on the C18 column (Supplemental Figure 3.12, 3.13).
In wildtype worms, exposure to DDT altered the metabolism of several amino acids (Figure 3.5 C),
in addition, in the aggregating tau strain, DDT also altered TCA cycle metabolism and glyoxylate
and dicarboxylate metabolism (Figure 3.5 C). In both strains exposed to DDT, the drug metabolism
pathways were enriched. The aggregating tau strain showed altered folate biosynthesis along with
several amino acid pathways, compared to the non-aggregating tau strain (Figure 3.5 C).
3.3.6 DDT has no effect on learning or protein aggregation
There was no difference in learning determined through the short-term associative learning
paradigm among the three strains. Further, exposure to DDT did not show an effect on learning
(Figure 3.7 A and B). Protein aggregation determined through congo red staining showed higher
levels of aggregates in the aggregating tau strain compared to the non-aggregating tau strain. DDT
increased the proportion of worms with aggregation in the aggregating and non-aggregating strains
however this increase was not statistically significant (Figure 3.14).
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Figure 3.4: Aggregating tau protein and DDT inhibit mitochondrial respiration. The wildtype and
non-aggregating tau strain showed similar oxygen consumption rates (OCR) however exposure to
DDT reduced the OCR in both strains (A). The aggregating tau strain showed a reduced OCR com-
pared to the wildtype and non-aggregating strain and exposure to DDT reduced basal respiration
in the aggregating tau strain (B). Each bar represents the mean respiratory measure made across
3-5 experiments with 7-12 wells per run with 3-30 worms per well. The error bars represents the
standard deviation. * p < 0.05, p < 0.0001.
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Figure 3.5: A. A heatmap with the top 50 features altered hierarchically clustered shows that in
all strains, DDT lowers the levels of several features. In B, a PCA biplot of PC1 and PC2 shows
strains exposed to DDT cluster differently from the wildtype and non-agg control strains. The
agg strain does not cluster with the wildtype and non-agg control groups, suggesting variation as
a result of aggregating tau protein expression. C shows the different metabolic pathways enriched
in the three different comparison groups. Enrichment is calculated as the ratio of the number of
significant hits and the total pathway size.
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Figure 3.6: Levels of uric acid are higher in all worms exposed to DDT (A) and levels of adeno-
sylselenohomocysteine are higher in worms exposed to DDT (B) and in worms expressing aggre-
gating tau protein.
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Figure 3.7: Associative learning was not affected by exposure to DDT in any of the strains. The
aggregating tau strain did not learn differently from the non-aggregating or wildtype worms. Each
bar represents the learning index (B), calculated as the difference between the trained chemotaxis
index, post-conditioning, and the naïve chemotaxis index (A).
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3.3.7 Developmental exposure to DDT blunts the lifespan reduction caused by aggregating tau
protein
The non-aggregating and aggregating tau strains have a shorter lifespan compared to the wild-
type worms (Figure 3.8 A). Exposure to DDT does not alter the lifespan in wildtype or the non-
aggregating tau strain. In the aggregating tau strain, exposure to DDT slightly rescued the reduction
in lifespan in the strain, however, the lifespan was still shorter than that of the non-aggregating and
wildtype strain (Figure 3.8 A and B).
3.4 Discussion
The use of DDT in the US was banned in the 1970s, however, due to its environmental per-
sistence and ability to accumulate in body lipids, it remains a significant exposure in the adult
population. Additionally, DDT can be passed through breastmilk to infants, exposing generations
that have been born since its ban (Needham et al. 2011). DDT is still used for vector control in
some African and south Asian countries. An analysis of global trends in production and use of
DDT found that in 2014, 3491 metric tons of DDT was produced and 3771 metric tons were used
for control of malaria and leishmaniasis (Berg, Manuweera, and Konradsen 2017). Furthermore,
DDT produced and released in lower latitudes can travel long distances through evaporation, dis-
tillation, and transport via winds and ocean currents. DDT, like other POPs, tends to move towards
higher latitudes and accumulates near the poles, endangering ecosystems that are far away from
the source of the pollution (Wania and Mackay 1996).
A recent cross-sectional metabolomics analysis found an association of a halogenated chemical
(related to DDT) with AD (Niedzwiecki et al. 2019a). However, it remains unknown if exposure
to DDT can cause or exacerbate AD symptoms. In-vitro, exposure to DDT and DDE has been
associated with increased levels of amyloid precursor protein (APP), a known risk factor of AD
(Richardson et al. 2014). However, to the best of our knowledge, there is no study that describes
the relationship between intracellular tau aggregates and its interaction with DDT.
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Figure 3.8: Survival analysis. The non-aggregating and aggregating strain live shorter than wild-
type worms. Exposure to DDT did not affect the survival of the wildtype or non-aggregating strains
however, exposure to DDT slightly rescued the reduced lifespan in the aggregating strain. The Ka-
plan Meier curves (A) are generated by following 60 – 120 worms in each group and the bars (B)
represent the mean lifespan in days and the error bars represent the standard deviation.
59
We investigate whether exposure to DDT can exacerbate tau protein toxicity using a transgenic
C. elegans strain that expresses human tau protein and a mutated tau protein sequence, associated
with frontotemporal dementia and Parkinson’s (FTDP-17), which has a propensity to form tau
protein aggregates (BR5270, referred to as the “agg” strain). We also use a transgenic strain to
serve as control for the agg strain which expresses the same human tau protein but the mutated tau
protein sequence is not prone to aggregation (BR5271, referred to as the “non-agg” strain). These
transgenes are expressed in all neurons of the worm driven through the rab-3 promoter (Fatouros
et al. 2012).
A survey of serum samples analyzed for levels of p,p’-DDT conducted by NHANES showed
a wide range of the pesticide in the blood of the American population, and levels of DDT mea-
sured increased with increasing age. Among those aged 12-19 years in the survey, the age range
with the lowest level measured, the geometric mean of lipid adjusted serum p,p’-DDT level was
less than 5 ng/g lipid (National Report on Human Exposure to Environmental Chemicals | CDC
2020). Assuming the wet mass of a single worm is 1 `g (Muschiol, Schroeder, and Traunspurger
2009), exposure to 3 `M DDT using our paradigm resulted in a mean level of about 0.5 ng/g wet
weight of C. elegans. The quantitative high-resolution GC-MS assay detected and measured sev-
eral metabolites of p,p’-DDT in worms exposed to the pesticide, suggesting that the pesticide is not
only absorbed but also biotransformed in the nematode, supporting the use of this model to study
the toxic effects of DDT. Previously, Mahmood (Mahmood 2016) found that exposure to 1 `g/ml
of DDT (corresponds to ∼2.8 `M) had a mild inhibitory effect on pharyngeal pumping, while this
dose had no effect on brood size. Thus, we exposed the wildtype, agg, and non-agg strains to 3
`M DDT during development and measured the effect of exposure on swim behavior, respiration,
growth, metabolism, learning, and lifespan.
In our study, similar to previous findings (Fatouros et al. 2012), we find that the agg strain
travels slower than the wildtype worms. The agg strain also showed a reduced wave initiation
rate, which is akin to a stroke rate (Restif et al. 2014), compared to the non-agg and wildtype
strain. Additionally, the agg strain had a lower overall activity index compared to the non-agg and
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wildtype strain. Exposure to DDT significantly increased the amount of time the agg strain spent
curling. The curling phenotype has been used to screen for motility defects in worms. A recent
screen for curling identified the bcat-1 gene to be associated with a Parkinson’s-like phenotype
and knockdown of the gene transcript showed altered mitochondrial function (Mor et al. 2020).
Furthermore, the curling phenotype was also used to ascertain dopaminergic toxicity due to the
complex I inhibitor, MPP+ (Braungart et al. 2004; Richardson et al. 2005).
We find that the agg strain has severely impaired mitochondrial respiration. Compared to the
non-agg strain, it has diminished basal and maximal respiration. Several in vitro and in vivo studies
have shown that aggregating tau protein can inhibit complex I and V of the mitochondria (David
et al. 2005; Kim et al. 2001; Lasagna-Reeves et al. 2011). It can alter the mitochondrial mem-
brane potential, cause activation of the apoptotic-related caspase-9, and impede energy production
(Lasagna-Reeves et al. 2011; Shafiei, Guerrero-Muñoz, and Castillo-Carranza 2017). These ef-
fects would manifest as increased production of reactive oxygen species and decreased production
of ATP. Furthermore, disintegration of tau protein can lead to disturbed transport of mitochondria
across microtubules and mitochondrial fission-fusion dynamics (Eckert et al. 2014; Fatouros et
al. 2012).
Exposure to DDT in the wildtype and non-agg strain severely impaired mitochondrial respira-
tion at baseline and when the membrane potential is uncoupled. Several in vitro and in vivo studies
have reported an inhibitory effect of DDT on mitochondrial function and ATP production, but none
have reported this in C. elegans. DDT is known to inhibit complex II, III and V of the electron
transport chain and it depresses the mitochondrial membrane potential (Elmore and La Merrill
2019; Moreno and Madeira 1991). In rats, exposure to DDT reduced the number of mitochondria
measured in the liver and altered fatty acid metabolism (Liu et al. 2017).
We find that the agg strain is smaller in size at larval stage 4 and in adulthood compared to the
non-agg strain. This could be attributed to reduced energy production and biomass accumulation
due to mitochondrial inhibition. When the strains are exposed to DDT, there is no difference in
size between the agg and non-agg strains exposed to DDT at larval stage 4, however the agg strain
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exposed DDT are significantly smaller adults than the non-agg strain exposed to DDT. It is likely
that the additional insult on the mitochondria by DDT restricts growth which is only detectable
post-development. High resolution metabolomics found several features to be altered in worms
exposed to DDT. Levels of several amino acids were reduced along with intermediates of the TCA
cycle and branched chain amino acid metabolism. A feature annotated as uric acid was increased
in all strains exposed to DDT (Figure 3.6 A). Uric acid is the end product of purine metabolism
and has anti-oxidant properties since it can scavenge free radicals and prevent lipid peroxidation
(Hooper et al. 1998). High levels of uric acid have been reported to induce stress response pathways
in C. elegans by increasing levels of the DAF-16/FOXO and SKN-1/NRF-2 transcripts (Wan et
al. 2020). Levels of adenosylselenohomocysteine were also found to be increased in all strains
exposed to DDT and in the agg strain (Figure 3.6 B). Thioredoxin reductase-1 (TrxR-1) is the
only selenium containing protein in C. elegans, expressed in the cytoplasm (Rohn et al. 2018).
An elevated seleno-metabolite suggests increased levels of TrxR-1 in response to oxidative stress
induced by DDT exposure and tau protein aggregation.
The agg strain did not show any difference in their ability to learn following an associative
training paradigm, compared to the non-agg or wildtype strain. These findings are similar to those
made by Wang and colleagues (Wang et al. 2018). Exposure to DDT did not affect the ability of
either strain to learn.
We found that the non-agg and agg strain have a reduced lifespan compared to wildtype worms,
replicating previous findings (Wang et al. 2018). The proteotoxicity and reduced respiratory rate
in the agg strain could explain this observation (Zarse et al. 2007). Interestingly, exposure to DDT
did not change the mean lifespan in wildtype or non-agg worms but it slightly increased the mean
lifespan of the agg strain. This finding is surprising but given that the exposure occurred develop-
mentally, it hints to the activation of mitohormetic pathways which could turn on lifespan extension
pathways (Maglioni et al. 2019), like the mitochondrial unfolded protein response (UPRmt) path-
way. However, the extension in lifespan was not large enough to be as much or more than the
lifespan of the non-agg or wildtype strain. It is also possible that while under normal conditions,
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mitochondrial inhibition by aggregating tau protein does not induce the UPRmt pathways but the
mitochondrial stress induced by DDT during development results in an antagonistic effect which
induces stress response pathways (Wytock et al. 2020).
While we present evidence in support of using C. elegans as model to study whether DDT
can exacerbate tau protein toxicity, our study has a few limitations. The C. elegans genome does
not encode for voltage gated sodium channels (Hobert, 2018), thus DDT does not produce neu-
rotoxicity through this mechanism in the nematode. However, this is not the only target through
which DDT exerts its toxicity. In the transgenic model we chose, we are unable to control the
level of tau protein aggregates expressed in the neurons. It is possible that the severe tau protein
aggregation toxicity is obscuring effects of DDT and its interaction with the proteotoxicity. The in-
teractions between the two insults may become more apparent when lower levels of the aggregates
are expressed.
Despite these limitations, we provide evidence that support the use of C. elegans as a model
to study gene x environment interactions. We provide evidence that DDT is absorbed and bio-
transformed by C. elegans. In wildtype worms, DDT restricts growth, as measured by size, and
reduces mitochondrial respiration measured using a Seahorse respiratory analyzer. DDT produces
major changes in global metabolism including pathways related to amino acid metabolism, drug
metabolism, ubiquinone biosynthesis, and riboflavin metabolism. In transgenic worms that ex-
press an aggregating form of human tau protein in all neurons, DDT restricts growth even further
and reduces the basal respiration rate. Aggregating tau worms exposed to DDT spend more time
curled up when swimming, a known mitochondrial toxicity phenotype. Further, DDT affects the
metabolism of several amino acids, the TCA cycle, and the glyoxylate and dicarboxylate metabolic
pathway. Our data suggest that exposure to DDT likely exacerbates the mitochondrial inhibitory
effects of aggregating tau protein in C. elegans.
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Figure 3.9: In A, the levels p,p’-DDT and its metabolites detected in wildtype worms exposed to
three different doses of: 0.3, 3, and 30 `M p,p’-DDT. In B, levels of p,p’-DDT and its metabolites
in wildtype, agg and non-agg strains exposed to 3 `M p,p’-DDT.
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Figure 3.10: Six different swim behaviors measured in wildtype, agg, and non-agg worms exposed
to DDT including asymmetry, attenuation, brush stroke, reverse swim, stretch and body wave
number. The agg strain spent more time swimming in reverse than the other strains or treatments.
The agg strain also has a lower brush stroke compared to the wildtype worms. None of the other
swim behaviors were different between the different strains or treatments.
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Figure 3.11: The heatmap shows levels of metabolitees annotated through WormJam.
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Figure 3.12: The heatmap shows levels of metabolitees annotated through WormJam.
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Figure 3.13: The heatmap shows levels of metabolitees annotated through WormJam.
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Figure 3.14: The agg and non-agg strain exposed to DDT show higher number of aggregates than
their solvent control however this difference was not significantly different.
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Chapter 4: Metabolic consequences of tau protein toxicity: from
Caenorhabditis elegans to humans
4.1 Introduction
1Tau is a microtubule associated protein that is found primarily in neuronal axons. It binds
to tubulin in axonal microtubules where it stimulates microtubule assembly and stability which
is important for axonal function and transport. It is a phosphoprotein with more than 30 poten-
tial phosphorylation sites. The binding of tau to microtubules is regulated by the phosphoryla-
tion/dephosphorylation equilibrium of tau (Josephs 2017). In Alzheimer’s disease (AD), and other
tauopathies, abnormally hyperphosphorylated tau leads to the formation of intracellular tangles.
Phosphorylated tau (p-tau) protein can be detected and measured in the cerebrospinal fluid. In AD
patients, there is a moderate to marked increase in CSF p-tau protein. CSF levels of p-tau probably
reflect the phosphorylation state of tau in the brain, possibly indicating the formation of tangles in
the AD brain.
The nematode Caenorhabditis elegans (worms) has been used as a model to study aging, cogni-
tive function, and neurodegeneration. Worms have a complex nervous system in which the major
mammalian neurotransmitter/ neuropeptide signaling components are conserved. They have or-
thologs for 60-80% of human genes, including highly conserved metabolic, transcriptional, and
protein biochemical machinery. The organism’s short lifespan (2-3 weeks) makes it ideal to study
aging and age-related pathology. Many long-lived mutants have been identified in C. elegans
and the insulin/insulin-like growth factor-1 signaling (IIS) pathway, the first established lifespan-
1Portions of this material were published as: Kalia, V., Jones, D.P., and Miller, G.W. (2019). Networks at the
nexus of systems biology and the exposome. Current Opinion in Toxicology.
Kalia, V., Bradner, J., Niedzwiecki, M., Lau, F., Bucher, M., Manz, K., Coates Fuentes, Z., Pennell, K., Walker, D.I.,
Picard, M., Hu, W., Jones D.P., Miller, G.W. Cross-species metabolomic analysis of DDT and Alzheimer’s disease-
associated tau toxicity. In preparation.
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regulating signaling pathway, was discovered in C. elegans, supporting its use in studies of aging.
In addition, C. elegans also have conserved metabolic components. Worm mitochondria show
close structural and functional conservation to mammalian mitochondria and pathways of inter-
mediary metabolism are also highly conserved. C. elegans is a useful model system to study
neurodegenerative diseases, including AD. In order to investigate the amyloid or aggregating tau
protein hypothesis of AD in C. elegans, transgenic strains that express aggregating amyloid or tau
protein in all worm neurons have been created. Studies using these transgenic strains showed al-
tered cognition with age and reduced lifespan. Using in vitro models, like C. elegans, allows us
to control for confounding variables that may cloud the effect of a perturbation on an outcome.
While human studies provide a more direct translation of exposure and effect, the worm model
allows us to control for other molecular/biological factors that can affect the relationship between
an exposure and effect.
There is evidence of aggregated tau protein affecting metabolism in the brain. Using PET trac-
ers that target tau neurofibrillary tangles, studies have reported an association between increased
PET tracer binding and decreased glucose metabolism (Bischof and Park 2015; Ossenkoppele et
al. 2015; Ossenkoppele et al. 2016). Through in vitro studies, there is evidence that pathological
tau expression is negatively associated with mitochondrial trafficking, morphology and bioener-
getics. p-tau is also associated with reduced ATP production, and imbalanced calcium buffering
capacity (Pérez, Jara, and Quintanilla 2018).
Researchers have investigated changes in proteins associated with tau protein expression (Hales
et al. 2016). These protein changes may act as catalysts and modifiers of metabolites. Given the
evidence of mitochondrial dysfunction as a result of tau-protein aggregation, an obvious solution
is to measure mitochondrial function. However, it known that the mitochondria host several im-
portant metabolic pathways which affect a lot of metabolites. Thus, evidence suggests that we
should assess which metabolomic features associated with aggregating tau protein expression are
conserved.
The advent of omics techniques that generate high-dimensional and unbiased measures of cel-
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lular function demand methods that can organize measures of many cellular molecules into in-
terpretable functional and/or physical structures. Systems biology has leveraged principles from
graph theory and network science to achieve this organization. Network science provides a frame-
work that can help interpret the behavior of molecules that are correlated, covary and form an
organized structure: a network. These functional networks can be thought of as a collection of
nodes, with a pair of nodes being connected to each other via edges. The edges may contain
information about the strength, direction, or quality of the relationship between the two nodes.
This overall structure of a network is similar across different disciplines, making it possible to
borrow computational methods while requiring domain-specific interpretation of results (Barabási
and PÃ3sfai 2016; Dančík, Basu, and Clemons 2013). Many have shown that networks in biology
tend to be scale-free and exhibit “small-world” network characteristics (Barabási and Oltvai 2004;
Zhu, Gerstein, and Snyder 2007). This type of organization shows the presence of key hubs, i.e.
influential nodes, that regulate many downstream processes. Biologists believe this affords some
amount of resiliency through redundancy while highlighting the importance of key regulators.
Emerging concepts of complex disease recognize that toxicity due from endogenous dysfunc-
tion or exogenous exposures are strong drivers of function and pathological disease processes,
with the caveat that individual responses to such exposures will be variable. Thus, while exposures
and responses differ between individual patients, they ultimately coalesce as disruptions to normal
homeostatic processes. This is true also in model organisms where variability in response is seen
between different organisms even though they have the same genetic background. A window into
changes in underlying homeostatic pathways offers a more sensitive look at effects of exposure.
Approaches that identify disruptions in evolutionarily conserved pathways that are associated with
Alzheimer’s disease related pathology offer great power for mechanistic interpretation, as corre-
lation between features observed across species provides a means to identify overlapping central
networks and interacting sub-networks associated with AD-related pathology.
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4.2 Methods
4.2.1 C. elegans growth and maintenance
Standard methods of culture including the use of normal or high growth media (NGM/ HGM)
plates, culture temperatures of 20 ◦C and the OP50 E. coli strain as a food source were followed as
described (Brenner 1974). C. elegans strains were provided by the CGC, which is funded by NIH
Office of Research Infrastructure Programs (P40 OD010440). These include the wild type N2 Bris-
tol strain, BR5271 (byIs162 [Prab-3::F3(delta)K280 I277P I380P + Pmyo-2::mCherry]; referred
to as the “non-agg” strain), and BR5270 (byIs161 [Prab-3::F3(delta)K280 + Pmyo-2::mCherry];
referred to as the “agg” strain).
4.2.2 C. elegans collection for HRM
A synchronized population of worm eggs were allowed to hatch and grow on NGM plates until
the L4 stage. Worms were then washed 4x using M9 and sorted into five-to-six replicates using
a COPAS FP-250. The final volume was reduced to 100 `l and each sample was snap frozen in
liquid nitrogen and stored at -80 ◦C until needed for high-resolution metabolomics processing.
4.2.3 Whole worm HRM analysis
Metabolites were extracted using acetonitrile (in a 2:1 ratio). The extraction solvent also con-
tained an internal standard. Bead-beating was used to disrupt the worm cuticle and improve ex-
traction. A spatula-full ( 10 beads) of zirconium oxide beads (0.5mm, Yttria stabilized) from Next
Advance (Troy, NY) were added to each tube. Each sample was placed in the bead beater at 6.5
m/s for 30 seconds, allowed to equilibrate on ice for one minute, and placed in the beater for an-
other 30 seconds, at the same speed. All processing was performed on ice or in a cold room when
necessary. Untargeted high-resolution mass spectrometry was run at the Clinical Biomarkers lab at
Emory University using a HILIC column (positive mode) and C18 column (negative mode) using
chromatographic methods previously described (Liu et al. 2016). Mass spectral data was gener-
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ated on an orbitrap mass spectrometer on full scan mode, scanning for mass range 85 to 1250 Da.
Data were extracted using the R packages apLCMS (Yu et al. 2009a) and xMSanalyzer (Uppal
et al. 2013). (See appendix B for more detail)
4.2.4 Participants
Subjects were recruited from the Emory Cognitive Neurology Clinic and the Emory Alzheimer’s
Disease Research Center. This study was approved by the Emory University Institutional Review
Board. Each subject underwent a detailed evaluation including neurological examination and neu-
ropsychological analysis. Subjects with cognitive impairment or dementia also underwent routine
blood tests to rule out common reversible causes of cognitive dysfunction, and brain imaging to
rule out structural causes of dementia. Subjects were classified as having normal cognition (NC)
if there was no subjective cognitive complaint and neuropsychological analysis showed normal
cognitive functioning according to age, gender, education, and race and as having MCI (Albert
et al. 2011) or AD dementia (McKhann et al. 1984) according to NIA-AA criteria. (Niedzwiecki
et al. 2019a)
4.2.5 Sample collection
Plasma samples were collected and processed as described previously (Hu et al. 2015; Niedzwiecki
et al. 2019a). Briefly, 20 mL of whole blood was collected via phlebotomy between 8 am and noon
without overnight fasting and centrifuged at 4 ◦C at 1000 x g. Platelet-rich plasma was immedi-
ately removed without disturbing the cellular layers, aliquoted, labeled, frozen, and stored at 80
◦C until analysis within 2 h of collection. All subjects in the two studies also underwent CSF
collection via lumbar puncture with a 24-gauge atraumatic spinal needle into polypropylene tubes
(BD Falcon), immediately aliquoted (0.5 mL), labeled, frozen, and stored at 80 ◦C until analysis
within 30 min of collection. CSF AD biomarker analysis was performed as previously described
in a Luminex 200 platform, including levels of beta-amyloid 1-42 (AV42), total tau (t-Tau), and
tau phosphorylated at threonine 181 (p-Tau181) (Hu 2015). For inclusion into the study, all NC
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subjects must have t-Tau/AV42 < 0.39 (not consistent with Alzheimer’s disease), and all AD de-
mentia subjects must have t-Tau/AV42 ≥ 0.39 (consistent with Alzheimer’s disease) based on a
previously published CSF autopsy study.
4.2.6 Plasma and CSF HRM analysis
Plasma and CSF samples were prepared for HRM using methods detailed elsewhere (Park et
al. 2012; Soltow et al. 2013; Go et al. 2015b). Briefly, aliquots were removed from storage at -80 ◦C
and thawed on ice, upon which 65`L of biofluid was added to 130 `L of acetonitrile containing a
mixture of stable isotopic standards, vortexed, and allowed to equilibrate for 30 min. Proteins were
precipitated by centrifuge (16.1 xg at 4 ◦C for 10 min), and extracts were stored in a refrigerated
autosampler. Triplicate 10 `L aliquots were analyzed by reverse-phase C18 liquid chromatog-
raphy (Dionex Ultimate 3000) and Fourier transform mass spectrometry in positive electrospray
ionization mode, resolution (FWHM) of 70,000 and mass-to-charge (m/z) range of 85–1250 (Ac-
cardi 2016, Walker 2016). Samples were grouped by matrix, randomized, and analyzed in batches
of 20, with a quality control (QC) pooled reference sample included at the beginning and end of
each batch. Raw data files were extracted using apLCMS (Yu et al. 2009a) with modifications by
xMSanalyzer (Uppal et al. 2013), with each unique mass-to-charge (m/z) feature defined by m/z,
retention time, and ion abundance.
4.2.7 Analysis of C. elegans data
The two feature tables generated from data acquisition were treated similarly. First, the inten-
sity of a feature in the samples was compared to its intensity in the medium blank (M9 buffer).
If the intensity was at least more than 1.5 times the intensity in the blank samples in all sam-
ples, it was retained for downstream analysis. Second, if a feature was missing from less 50%
of the samples, it was imputed with half the value of the minimum intensity measured. Features
missing from more than 50% of the samples were removed from downstream analysis. Third, the
filtered and imputed feature table was imported into MetaboAnalyst (Pang et al. 2020) and nor-
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malized by generalized log transformation. The normalized feature table was used to determine
the metabolomic profile associated with the agg worms by comparing features from the agg and
non-agg worms. The intensity of each feature in each group was tested using a t-test. The fea-
tures of significance were analyzed for pathway enrichment using the mummichog algorithm (Li
et al. 2013) on MetaboAnalyst using the C. elegans KEGG reference map.
4.2.8 Analysis of patient data
Variation in m/z feature intensities related to analytical daily batch was removed using ComBat
(Leek et al. 2012). Associations of m/z features with p-tau levels were assessed using an MWAS
approach (Holmes et al. 2008; Bictash et al. 2010) for features present in >80% of study samples
controlling for sex, age and batch of analysis. Features associated with p-tau levels were analyzed
for metabolic pathway enrichment using mummichog version 2.0.6 (Li et al. 2013).
;>6()8, 9 ) = V0 + V1?C0D 9 + V2B4G 9 + V3064 9 + V410C2ℎ 9 + Y8, 9
Where, For each subject 9 , )8 is the normalized intensity of feature 8 . . . <, ?C0D 9 is the levels
of phosphorylated tau measured in their CSF, 064 9 is their age in years, B4G 9 is their sex, and
10C2ℎ 9 is the analytical batch in which the plasma or csf sample was analyzed for metabolomics.
4.2.9 Comparing results across the two species
Features that were significantly associated with tau protein in the CSF or neuronal expression
in worms with p < 0.05 were compared overlap. Annotation made through mummichog allowed
the feature identification. To determine the statistical significance of the overlap, a permutation test
was conducted by randomly sampling the number of features significantly altered in worms and
humans from their list of annotated metabolites and discerning the number of overlapping metabo-
lites. A distribution of overlap by chance was created and the probability of overlap observed was
determined.
All statistical analyses were performed in RStudio v1.1.456.
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Figure 4.1: Changes in global metabolism associated with aggregating tau protein in C. elegans.
The pro-aggregating tau strain shows wide-spread change in global metabolism. In A, a PCA biplot
shows the variability of features that load onto PC1 and PC2. The aggregating tau strain clusters
differently from the non-agg and wildtype worms. In B, a metabolome wide association study
found 900 features significantly different between the agg and non-agg worms. These features
enriched several pathways, shown in C, as determined using the mummichog algorithm.
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4.3 Results
4.3.1 Aggregating tau protein expression in C. elegans produces changes in global metabolism.
The LC-HRMS analysis measured 19,380 features in the HILIC column under positive mode.
After blank filtration and imputation, a total of 8860 features were retained for further analysis.
The metabolome wide association analysis found 900 features significantly different between the
agg and non-agg strain (Figure 4.1 A). These significantly different features were analyzed for
pathway enrichment using the mummichog algorithm hosted on MetaboAnalyst using the KEGG
C. elegans reference map. The pathways enriched included pathways identified in chapter 3 like the
tryptophan and arginine pathway, implicating altered amino acid metabolism. Other pathways that
have been associated with neurodegeneration and AD were also enriched, like the glycerophos-
pholipid pathway, lysine degradation, glutathione metabolism, as well as glutamate and glutamine
metabolism (Figure 4.1 C). Features annotated against an in-house reference library found reduc-
tion in levels of several choline metabolites in the agg strain compared to the non-agg and wildtype
worms (Figure 4.2 A, B, C).
4.3.2 Demography of AD and MCI patients
Patients with a diagnosis of Alzheimer’s disease (AD) or mild cognitive impairment (MCI)
were included in the analysis. Of these patients, 142 plasma and 78 CSF samples were analyzed
using the LC-HRMS method. There were no significant differences in the distribution of age or
gender between the three different diagnoses. Patients with AD and MCI had higher levels of p-tau
measured in their CSF compared to controls (Table 4.1).
4.3.3 CSF metabolism and CSF p-tau levels
After cleaning, a total of 6028 features were detected and measured in the CSF of patients.
After controlling for the age, sex, and batch of analysis, we found 225 features to be associated
with CSF levels of p-tau with a p < 0.05. Pathway analysis using these features suggested changes
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Figure 4.2: Choline metabolites are reduced in the aggregating tau strain. Using an inhouse ref-
erence library, several features annotated as choline metabolites were found to be reduced in the
aggregating tau strain compared to the non-aggregating and wildtype worms. Features in A, B, and
C are significantly reduced (FDR<0.1) between the agg and non-agg worms. In D, we show a fea-
ture annotated using the inhouse reference library as phenethylamine which was no significantly
reduced in the agg strain.
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Table 4.1: Demographics of patients with AD and MCI
PLASMA
Control AD MCI
n = 46 n = 45 n = 51
% Male 30% 35% 48%
Age (y) 66.5 ± 8.7 65.9 ± 8.9 69.4 ± 6.6
CSF protein biomarkers
AV42 (pg/mL) 336 ± 137 201 ± 76 218 ± 90
t-Tau (pg/mL) 44 ± 23 120 ± 66 76 ± 70
p-Tau181 (pg/mL) 32 ± 14 74 ± 30 51 ± 25
CSF
Control AD MCI
n = 25 n = 26 n = 27
% Male 28% 38% 55%
Age (y) 66.2 ± 8.2 64.8 ± 8.2 70.2 ± 6.2
CSF protein biomarkers
AV42 (pg/mL) 323 ± 125 191.8 ± 58 217.1 ± 81
t-Tau(pg/mL) 44 ± 24 113 ± 64 69 ± 44
p-Tau181 (pg/mL) 32 ± 13 79 ± 32 53 ± 20
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in pathways associated with glutamate metabolism, carnitine metabolism, lysine metabolism, sat-
urated fatty acid metabolism as well as metabolism of several amino acids (Figure 4.3 A and
B). The top six features measured in the CSF associated with p-tau levels were 6-acetamido-2-
oxohexanoate, N,N-dimethylglycine, glutamine, 2-aminoacrylate, eicosatetranoyl carnitine, and
5-aminolevulinate (Figure 4.5)
4.3.4 Plasma metabolism and CSF p-tau levels
After cleaning, a total of 7249 features were used to assess the relationship between the plasma
metabolome and levels of p-tau measured in the CSF of the patients. A metabolome-wide associ-
ation study controlling for the age, sex, and batch of analysis found 391 features to be associated
with p < 0.05. Pathway analysis using these features suggested changes in pathways associated
with drug metabolism, carnitine metabolism, lysine metabolism, and pathways associated with en-
ergy production (Figure 4.3 C and D). The top six plasma-derived features associated with CSF
p-tau levels were monoethylglycinexylidide, glutamine, palmitoyl carnitine, linolenyl carnitine,
hydroxylidocaine, and tetradecanoyl carnitine (Figure 4.4).
4.3.5 Features associated with aggregating tau protein in both species
The overlap between the two species was conducted separately for the two human matrices.
A feature associated with CSF p-tau levels or aggregating tau protein expression was deemed
significant at a nominal p-value < 0.05. These significantly associated features were annotated
through mummichog and overlap in the KEGG ID annotation was determined. A total of 10
unique annotations were found to overlap between features associated with the agg strain and
plasma metabolomics features associated with CSF p-tau (p-value from permutation test = 0.6), and
around 8 unique annotations were found to be overlapping between the features of significance in
the agg strain and CSF-derived features associated with CSF p-tau levels (p-value from permutation
test = 0.9). Concordance between the two species was determined by the direction of the change.
Features that were similarly changed in both species were marked as concordant (Table 4.2 and
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Figure 4.3: Plasma and CSF-derived features associated with CSF p-tau levels. In A, a
metabolome-wide association study found 225 CSF-derived features associated with CSF p-tau
levels with p < 0.05. These features enriched several pathways, determined using mummichog,
shown in B. In C, 391 plasma-derived features were found to be associated with CSF p-tau levels,
with p < 0.05, and the pathways enriched by these features are listed in D. Association models for
features from both matrices were adjusted for sex, age, and the batch of sample analysis.
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Figure 4.4: CSF-derived feature associated with CSF p-tau. In each panel, we show the relationship
between intensity of the top-6 features associated with CSF p-tau (y-axis) and CSF levels of p-tau
measured (x-axis).
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Figure 4.5: Plasma-derived feature associated with CSF p-tau. In each panel, we show the rela-
tionship between intensity of the top-6 features associated with CSF p-tau (y-axis) and CSF levels
of p-tau measured (x-axis).
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Table 4.2: Overlap between plasma-derived features and features measured in C. elegans associ-
ated with tau protein





















































(p = 0.032) Yes
a Higher/lower in the aggregating tau strain (p-value)
b Association with CSF p-tau levels (p-value)
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Table 4.3: CSF-derived features, associated with CSF p-tau levels, overlapping with features asso-
ciated with tau protein in C. elegans









































(p = 0.015) No
a Higher/lower in the aggregating tau strain (p-value)




Evolutionary conservation is usually determined by comparing similarity in sequence homol-
ogy across different species. Here, I attempt to find similarities between two species by measuring
changes in systemic biochemistry related to a cellular perturbation associated with Alzheimer’s
disease.
Model organisms provide a useful tool to understand age-related changes in biology and pathol-
ogy, while being amenable to experimental manipulation. A number of signaling pathways that act
as master regulators of aging and lifespan are conserved in yeast, nematodes, flies, and mammals
(Bishop, Lu, and Yankner 2010). In fact, work in model systems has uncovered evolutionarily
conserved pathways that regulate both longevity and age-related changes in learning and memory
(Bishop, Lu, and Yankner 2010; Klass 1977; Friedman and Johnson 1988; Kauffman et al. 2010;
Kenyon et al. 1993; Grotewiel et al. 2005; Silva et al. 1998). We have adopted the nematode
Caenorhabditis elegans as our model organism to study aging and cognitive function. The organ-
ism’s short lifespan (2-3 weeks) makes it ideal to study aging and age-related pathology (Ardiel
and Rankin 2010; Arey and Murphy 2017; Jonsson et al. 2013). Many long-lived mutants have
been identified in the model (Uno and Nishida 2016) and the insulin/insulin-like growth factor-1
signaling (IIS) pathway, the first established lifespan-regulating signaling pathway, was discov-
ered in C. elegans, supporting its use in studies of aging (Kenyon et al. 1993). C. elegans are a
good model to study neurodegenerative diseases, especially AD (Link 2006). Although C. ele-
gans have an amyloid precursor protein (APP) homolog they do not possess the AV sequence or
the enzyme -W-secretase, both essential for producing extracellular AV that can aggregate to form
plaques (Link 2006; Daigle and Li 1993). In order to investigate the amyloid hypothesis of AD
in C. elegans, many transgenic strains have been generated in which AV is expressed driven by
tissue specific promoters, like unc-54 for expression in muscles and snb-1 for pan-neuronal ex-
pression of the AV. These models show age-dependent effects on movement, neurodegeneration,
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and cognitive function (Wang et al. 2018; Link 1995). C elegans also possess a tau homolog pro-
tein with tau-like repeats (Goedert et al. 1996; McDermott, Aamodt, and Aamodt 1996). It has a
high-level of sequence homology with mammalian tau. It is expressed mainly in the mechanosen-
sory neurons and evidence suggests it mediates the touch response, neuronal aging, and lifespan
(Goedert et al. 1996; Gordon et al. 2008). These models present an opportunity to study the molec-
ular interactions between environmental exposures and AD pathology in a controlled experimental
setting.
Many studies have described the behavioral plasticity of the nematode, mediated through the
302 neurons in its nervous system (Hobert 2003). By leveraging the associative and non-associative
behavioral plasticity in the model, several learning paradigms have been developed in C. elegans.
The retention of memory can be tested for short term associated memory (STAM) by determining
retention up to 2 hours. To test long-term associated memory (LTAM) retention, the conditioning
paradigm is prolonged and worms are tested up to 24 hours after conditioning. The LTAM retention
of memory is dependent on transcription, translation, and CREB activity (Kauffman et al. 2011).
CREB activity is also known to be required for long-term memory formation in flies, Aplysia, and
mice (Silva et al. 1998). These findings suggest that worms can be used to study evolutionarily
conserved molecular pathways involved in memory. With age, C. elegans show a decline in mem-
ory tested using associative learning paradigms. Additionally, transgenic expression of human A
peptide and tau co-expression impaired the performance of 1-day old adult worms on the STAM
assay, and this impairment was exacerbated when measured in 3-day old adults (Tynkkynen et
al. 2018).
Studies discussed above provide evidence of evolutionarily conserved molecular pathways that
are associated with aging and cognition. Besides, C. elegans mitochondria show close structural
and functional conservation to mammalian mitochondria (Murfitt, Vogel, and Sanadi 1976) and
pathways of intermediary metabolism are also highly conserved (O’Riordan and Burnell 1990).
Whether biochemical pathways associated with AD-pathology are also evolutionarily conserved
remains to be elucidated. Answering this question would provide novel insight into manifestations
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of AD-pathology and also validate C. elegans as a model to study AD. Literature suggests we will
identify pathways related to mitochondrial function, stress responses, and downstream metabolic
changes associated with aging-associated pathways like the IIS (Arey and Murphy 2017; Xue et
al. 2007; Jonsson et al. 2013).
While model organisms are used to study AD, pathology associated with the disease in humans
does not naturally precipitate in most organisms. Transgenic models of AD in C. elegans have
proved useful in understanding the disease but translation of findings is often questioned. Using a
systems biology approach, we can identify key metabolic network modules (Hartwell et al. 1999)
that are associated with the disease in humans and C. elegans to justify the use of C. elegans as a
model to study AD.
Using a transgenic strain of C. elegans that expresses a mutant form of human tau protein in
all neurons, I found several changes in global metabolism associated with aggregating tau protein.
Around 900 features were significantly different at FDR < 0.05 between the aggregating tau strain
and its control transgenic strain. These features enriched pathways that have previously been
associated with neurodegeneration and AD, including the glycerophospholipid pathway, amino
acid metabolism, glyoxylate and dicarboxylate metabolism, and vitamin B 6 metabolism (ref). AD
has been associated with a deficit in levels acetylcholine (ACh). Treatment of AD includes the use
of acetylcholinesterase inhibitors that can increase the levels of ACh in synapses. Using an inhouse
reference library, we found several features annotated with level 1 confidence as metabolites of
choline to be reduced in the aggregating tau protein strain.
Analysis of patient data showed results similar to findings made in this cohort previously
(Niedzwiecki et al. 2019a). In the plasma, the feature with the lowest p-value (monoethylglycinexy-
lidide) associated with levels of CSF p-tau derives from metabolism of Rivastigmine. Rivastigmine
is an acetylcholinesterase inhibitor prescribed to treat symptoms of reduced ACh in patients of AD.
Similar to the previous study, the level of CSF p-tau was positively associated with plasma levels
of glutamine. Several metabolites of carnitine in plasma were negatively associated with levels of
CSF p-tau while a lidocaine derivative is positively associated with levels of CSF p-tau.
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Metabolomic profiling of the CSF showed a negative association between CSF levels of p-tau
and glutamine, contrary to the direction of the association found in plasma. Levels of dimethyl-
glycine, a metabolite in the glycine, serine and threonine pathway was negative associated with
CSF p-tau levels. The metabolism of serine and glycine has been associated with AD previ-
ously (Angeloni, Zambonin, and Hrelia 2014). A member of the lysine degradation pathway,
6-acetamido-2-oxohexanoate is also negatively associated with levels of CSF p-tau. CSF levels
of a carnitine metabolite were found to be positively associated with increasing p-tau levels as
were levels of 5-aminolevulinic acid, a metabolite part of porphyrin metabolism. Lastly, levels of
aminoacrylate, a member of pyrimidine metabolism were found to be negatively associated with
CSF p-tau. The overlap analysis identified 5 unique metabolites that were affected similarly by
levels of p-tau in the CSF in the plasma of patients or by the presence of aggregating tau protein
in the neurons of worms and 4 unique metabolites from the CSF similarly affected in the worms.
Of these metabolites, levels of cystine were found to be overlapping with concordance in both
matrices and worms.
Plasma-worm overlap
Lipoamide is the amide form of lipoic acid. Lipoic acid is a naturally occurring disulfide com-
pounds which functions as a co-factor for mitochondrial bioenergetic enzymes: pyruvate dehydro-
genase and U-ketoglutarate dehydrogenase. It has been proposed a novel treatment for AD owing
to the many functions it performs (Holmquist et al. 2007). Lipoic acid has been reported to increase
acetylcholine production by activating choline acetyl transferase. It could improve the cholinergic
deficit that is associated with AD (Haugaard, Levin, and Surname 2000). LA has been associated
with increased glucose uptake (Holmquist et al. 2007) and has been reported to improve peripheral
insulin resistance and impaired glucose metabolism (Bitar et al. 2004; Thirunavukkarasu, Nand-
hini, and Anuradha 2004; Lee et al. 2005). Lipoic acid affects oxidative stress in multiple ways:
1. It can chelate redox-active transition metals and reduce the formation of hydrogen peroxide
and hydroxyl radicals (Suh et al. 2005), 2. It scavenges reactive oxygen species and is associated
with increased levels of reduced glutathione (Suh et al. 2004) and decreased inflammatory pro-
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cesses (Bierhaus et al. 1997; Wong et al. 2001), 3. It can scavenge lipid peroxidation products
(Gasic-Milenkovic, Loske, and Münch 2003).
Diethylthiophosphoric acid is identified as a part of the aminobenzoate degradation pathway,
specifically, a breakdown product of parathion degradation, an OP pesticide. While there is no
reason to expect a metabolite of parathion in C. elegans, the metabolite could share its m/z with
other products of the aminobenzoate degradation pathway (KEGG, https://www.genome.jp/kegg-
bin/show_pathway?map00627+C06607). Derivatives of aminobenzoic acid may have potential as
drugs to inhibit acetylcholinesterase, thereby ameliorating the ACh deficit present in AD (Shrivas-
tava et al. 2019).
11,12-Dihydroxy-5Z,8Z,14Z-eicosatrienoic acid (12,12 DHET) and other eicosanoids derive
from oxidation of arachidonic acid, a well-known precursor activated during an inflammatory re-
sponse. A study using strains of mice expressing AV and tau in the brain found increased levels of
several eicosanoids in the brain and in plasma of these mice (Tajima et al. 2013). In both human
plasma and worms we found higher levels of DHET. Eicosanoids can perform different functions
in relation to AD. They could be 1. pro-inflammatory, AD-promoting, 2. Anti-inflammatory, AD-
resolving, or 3. Have mixed effects depending on the context of cellular health. According to
Biringer (2019) (Biringer 2019), 11, 12 DHET likely functions in a context-specific way.
Altered lysine metabolism detected in the plasma has been previously reported in cases of MCI
compared to cognitively normal individuals (Trushina et al. 2013). Lysine supplementation has
been proposed as a treatment strategy for AD based on an infectious disease hypothesis of the
disease. The Herpes Simplex Virus (I) has been known to produce amyloid lesions and intra-
neuronal tangles in the brain that look similar to histopathology associated with AD (Eimer et
al. 2018; Rubey 2010). In 1982, Ball (Ball 1982) suggested that AD maybe caused by reactivation
of latent HSV-1 in the brain. Studies around the replication of the virus suggest that the virus
is suppressed in lysine rich and arginine poor environment, prompting researchers to follow-up
studies for benefits of lysine supplementation in AD. While we wouldn’t expect C. elegans to
show metabolic consequences of an HSV-1 infection, the finding could be related to depletion in
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Acetyl-lysine levels due to consequences of aggregating tau protein (Ali et al. 2018).
Cystine is the dimer (oxidized) form of cysteine, a sulfur containing amino acid that func-
tions to reduce redox stress. Cysteine is considered the rate limiting step in glutathione synthesis
(Banjac et al. 2008). It is suggested that increased conversion of cystine to cysteine functions to
create a reducing extracellular environment to reduce redox stress. Decreased levels of cystine in
the plasma, CSF, and worms could be a result of increased conversion of cystine to cysteine to
ameliorate oxidative stress. Several studies have reported increased levels of cysteine in the brain,
plasma, and CSF of AD pateints (Mahajan et al. 2020; Czech et al. 2012; Trushina et al. 2013).
CSF-worm overlap
Tyrosine is the precursor for synthesis of catecholamines. In the CSF of AD patients, several
studies have reported lower levels of tyrosine (Martinez et al. 1993; Basun et al. 1990). In an-
other study, CSF samples of MCI patients also analyzed at the Clinical Biomarkers lab at Emory
University showed altered tyrosine metabolism (Hajjar et al. 2020).
Carnitine is a quaternary ammonium compound that transports long-chain fatty acids into the
mitochondria to be oxidized for energy production. In our analysis, levels of free carnitine were
reduced in both CSF and worms in association with tau protein. Previously, lower levels of car-
nitine in the CSF have been reported in non-APOE Y4 carriers in the early stage of AD (Lodeiro
et al. 2014). Another study of CSF from AD patients found lower levels of free carnitine but
increased levels of acylcarnitine suggesting impaired energy production through anaplerotic path-
ways (Velpen et al. 2019).
N, N-dimethylaniline N oxide is classified under benzene and substituted derivatives. The
tertiary amino group in the molecule is oxidized to its corresponding N-oxide product. It is the
product formed by reaction between dimethylaniline, NADPH, oxygen and H+ catalyzed by the
dimethylaniline monooxygenase which requires FAD as a co-factor. The levels of this metabolite
are lower in both worms and the CSF in association with tau suggesting decreased conversion of the
dimethylaniline to the compound. There is no other information available in regard to neurodegen-
eration or Alzheimer’s disease (KEGG, HMDB, https://www.uniprot.org/uniprot/G5EDG8, ChEBI
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https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:17735).
The results from this analysis should interpreted with an abundance of precaution, I am after all
comparing the metabolic consequences of a perturbation in a microscopic nematode to metabolic
consequences of a more complicated perturbation in humans. However, the concordance between
several metabolites that have been previously associated with AD provides validity to using C.
elegans as a model to study biochemical changes associated with AD-related pathology.
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Chapter 5: Conclusion
Several environmental drivers of human health have been determined through the efforts and
rigorous research of several environmental epidemiologists. In order to determine the causal na-
ture of an association found in epidemiological studies, Bradford Hill created a list of criteria
that must be met by the exposure/cause in question (Hill 1965). Two of the criteria listed rely
on toxicological evidence of an effect: the presence of a biological gradient or dose response and
a plausible biological mechanism that can explain the relationship between the cause and effect.
While the utility of all the principles listed by Hill are debated (Fedak et al. 2015), it is easy to
realise the importance of biological plausibility when declaring a cause-effect relationship. Toxi-
cological studies using model systems allow for experimentation which is critical to tease apart the
relationship between an exposure and outcome and discover if biological plausibility exists.
Our environment can affect us in a number of ways. Adverse events during the life course
trigger stress responses, infections produce immunological responses, toxin, toxicant and pollutant
exposures usually disrupt several pathways and elicit a toxicological response, and climate change
can disrupt homeostatic responses. While it is possible to compartmentalize responses to the en-
vironment, these responses have the potential to affect one another. For instance, increased stress
can increase the susceptibility to infections (Marsland et al. 2002). On a cellular level, responses
are made every second based on signals received from the environment. Decisions made in the
nucleus produce change, via proteins, in levels of small molecules that perform a myriad of func-
tions, including the production of energy in the cell. These small molecules also report back to the
nucleus and drive decision making based on signals and feedback mechanisms.
The ability to alter physiological response by using drugs has been one of the greatest achiev-
ments of modern medicine. Using drugs, humans are able to fight against microbial invaders and
parasites and affect change in their own bodies that can help improve disease-associated disability
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and poor health. These drugs have been life-saving. Drugs are usually small molecules that func-
tion in many ways but most of them are designed to interact with receptors in very specific ways
in order to produce signals that affect how cells and tissues behave.
There are thousands of other small molecules that are produced in very large quantities every
day, which are not designed to alter human physiology. However, many of them are bioactive
and can produce a physiological response in the human body in unknown ways. Given the sen-
sitivity of cells to changes in the environment, the uncertainty of the toxic effects posed by these
chemicals (toxicants) is a threat to public health. As discussed in Chapter 1, more than 85,000
chemicals are registered with the EPA for manufacture, import, and use in commercial products
and approximately 112,000 chemicals and compounds are registered with the US Food and Drug
Administration as drugs or food additives. Exposure to these chemicals can occur through direct
consumption, like food or personal care products, or indirectly through compartments in which
these chemicals concentrate, like the air or water. Pollutants also pose a threat to human health,
like air pollution, which affects many facets of health. Apart from man-made sources of toxicants
and pollutants, chemicals that derive from natural sources (toxins), like metals and chemicals pro-
duced by algal blooms, can also adversely affect health.
Our ability to measure small molecules has been boosted by advances in mass spectrometry
technology. The advent of high-resolution mass spectrometers has made it possible to measure
molecules with low and high abundance in a biological matrix with high sensitivity. Thus, in
biological samples, we are able to measure relative levels of small molecules that derive from
endogenous sources (like metabolites), which are found in high abundance, and small molecules
in low abundance that derive from exogenous sources that entered the body after exposure and
remain persistent at the time of sample collection.
In this dissertation, I demonstrate the utility of high-resolution mass spectrometry (HRMS)
in measuring changes in small molecules associated with Alzheimer’s disease in a case-control
study designed using samples available from participants of the Washington Heights and Inwood
Columbia Aging Project (WHICAP, Chapter 2). I then follow-up an epidemiological finding made
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in a different case-control study where a metabolite of a persistent organic pollutant, dichlorodiphenyl-
trichloroethane (DDT), was found to be associated with AD, using the nematode model, Caenorhab-
ditis elegans (worms, Chapter 3). This inquiry used quantitative high-resolution mass spectrome-
try to measure levels of DDT and its metabolites that were detectable in worms exposed to DDT.
I also used HRMS to measure changes in global metabolism associated with exposure to DDT
and due to AD-related pathology in the worms. Next, I chose to discern if changes in levels of
small molecules associated with AD-related pathology are conserved between humans and worms
(Chapter 4). This systems biological approach bypasses the commonly used approaches of study-
ing particular biological pathways and allows an unbiased search of hundreds of pathways and
thousands of metabolites.
The ethnically diverse WHICAP cohort provides a rich source of data to study Alzheimer’s
disease (AD). Although there have been major advances in our understanding of AD genetics,
the non-genetic drivers of disease have lagged behind. In Chapter 2, using untargeted HRMS
I was able to determine that the endogenously derived small molecules (metabolites) ceramide,
carnitine, and the fatty acid octadecatetraenoic acid are associated with AD. Further, the exoge-
nously derived benzyl chloride and a benzene metabolite were also associated with AD. Cases and
controls of African American ethnicity showed a metabolomic profile which was different from
individuals of Caucasians or Caribbean Hispanic ethnicity. Furthermore, the gene with the greatest
risk for AD, the APOE-Y4 allele, was associated with several metabolic pathways. This untargeted
approach, which is now being expanding to include thousands of participants (the successful grant
applications utilized my data to demonstrate the potential of this approach).
The nematode C. elegans is a well described model traditionally used to address genetic and
neurological questions. Colloquially, the nematodes are often described simply as worms. There
has been an interest in using the model in toxicological studies given how well worm biology is
understood. In my quest described in Chapter 3, I find that expression of an aggregating form of
human tau protein, one of the key proteins thought to be involved in AD pathogenesis, in all the
neurons of the worm affects several aspects of metabolism. The worms showed altered growth
96
measured through size and slower travel speed. They show impaired mitochondrial respiration and
reduced levels of several metabolites. When this transgenic strain is exposed to DDT, it showed
greater deficits in basal mitochondrial function, swim behaviors associated with mitochondrial
inhibition, and widespread changes in levels of small molecules measured using HRMS.
Chapter 4 was an ambitious exploratory undertaking that dared to compare the small molecule
profile measured in a transgenic strain of the microscopic nematode to small molecules measured
in the cerebrospinal fluid and plasma obtained from patients and controls of AD. The study showed
concordance in a few metabolites between the two species that have been associated with AD in
several other human studies. This study bolsters the use of the nematode model to study metabolic
consequences of AD.
Model organisms provide scientists the opportunity to follow up findings made through ob-
servational studies in epidemiological contexts. For example, Yao et al (2018) (Yao et al. 2018)
present an approach (diseaseQUEST) that leverages gene expression information available on the
tissue-level in organisms like C. elegans to determine the importance of genes predicted to be as-
sociated with a human disease through genome-wide association studies. This approach then calls
for using model organisms to confirm the biological relevance of genes identified using behav-
ioral and pathogenic screens. As proof of principle, they tested 45 candidate Parkinson’s disease
genes across 13,255 individual worms. Neuronal knock-down of the top candidate gene, the bcat-
1 gene, was associated with spasm-like curling and exacerbated U-synuclein-mediated degenera-
tion of dopaminergic neurons (Yao et al. 2018). The effect of knock-down of the bcat-1 gene in
worms was followed up by Danielle Mor, a postdoctoral fellow in the Murphy Lab at Princeton.
Through cell-type specific transcriptomics, she reported changes in expression of genes associated
with metabolism and the TCA cycle in the neurons (Mor et al. 2020). The bcat-1 gene encodes
for the branched-chain amino acid transferase enzyme. It catalyzes the breakdown of branched-
chain amino acids: leucine, isoleucine and valine, into their U-keto acid derivatives (Mansfeld et
al. 2015). In collaboration with the Murphy Lab, I measured changes in global metabolism as a re-
sult of neuronal knockdown of the bcat-1 gene. We found changes in levels of several metabolites
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related to the TCA cycle as well as levels of branched-chain amino acids (Figure 5.1). Thus, we
were able to find changes in functional end points that corresponded to changes in levels of gene
expression determined through transcriptomics. Based on these findings made by the Murphy and
Miller Lab, we reinforce the utility of C. elegans in studying human disease and gleaning biologi-
cal insight from findings made in observational epidemiological settings (this work was published
in PNAS and, while not included in this dissertation, did provide the foundation for Chapters 3 and
4).
While there is mounting evidence that C. elegans are a good model to follow-up findings made
in population studies, how biologically relevant is the evidence? As it turns out, there is a high
degree of relevance in this simple model. Among the many benefits of using C. elegans is their
short life cycle and amenability to high-throughput toxicology. Observations made through expo-
somic analyses can be confirmed by systematic examination in worms by: 1. exposing worms to
different toxicants and/or 2. using the various mutants that are available at a very low cost. The
use of a combination of liquid and gas chromatography coupled to high-resolution mass spectrom-
eters used in an untargeted manner can capture many high and low boiling point small molecules
in human matrices. Using chemoinformatic and machine learning methods, we can determine the
relevance of different small molecules and biological pathways to an exposure or health outcome.
I envision following up the relevance of these exposures or biological pathways using C. elegans.
The biology of a worm is very well understood which makes it a good model organism to study
the biological effects of a perturbation through toxicant exposure or pathogenesis. Further, several
therapeutic agents can also be tested in C. elegans. There is a fair amount of precedent (O’Reilly
et al. 2014; Lucanic et al. 2018; Ikenaka et al. 2019) to use C. elegans for high-throughput drug
screening to ascertain target molecules that can protect or prevent the toxic effects of an insult.
Thus, we can look for therapeutic agents that could improve functional outcome in C. elegans to
identify potential drug candidates (Figure 5.2).
Understanding the relationship between the totality of environmental exposures and health
poses many challenges. Many exposures are largely involuntary, dynamic, and the environmental
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Figure 5.1: Metabolomics analysis reveals a depletion of TCA cycle metabolites in bcat-1(RNAi)
worms. Neuronal RNAi-sensitive worms were collected for metabolomics on day 5 following
adult-specific bcat-1 knockdown. (A and B) Manhattan plot (A) and heat map (B) showing fea-
tures that were increased (purple) and decreased (green) (P < 0.05) in bcat-1(RNAi) worms. The
color values in B represent relative intensities of features that have been log2-transformed and
centered. (C) Partial least squares-discriminant analysis. (D) Pathway analysis using the mum-
michog algorithm. (E) As expected, features putatively annotated as leucine/isoleucine and gluta-
mate were increased and decreased, respectively, in bcat-1(RNAi) worms. (F) TCA cycle metabo-
lites/precursors were decreased in bcat-1(RNAi) worms. n = 6 independent collections for control,
5 for bcat-1. Two-tailed t tests. *P < 0.05; **P < 0.01. Boxplots show minimum, 25th percentile,
median, 75th percentile, and maximum (Mor et al. 2020)
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Figure 5.2: Harnessing the power of model organisms. Using liquid and gas based chromatography
coupled with high-resolution mass spectrometry, we can measure levels of endogenous and exoge-
nously derived small molecules in different biological matrices. By using the appropriate study
design, we can identify candidate molecules and biological pathways associated with environmen-
tal exposures or disease in human populations. These candidates can be followed up by exposing
an appropriate C. elegans strain: transgenic strains, mutant strains, or strains that are susceptible
to RNAi based knockdown. Given their short life cycle and being amenable to high-throughput
behavioral assays, they can readily provide functional and molecular readouts of the perturbation.
The findings can provide leads for relevant policy around environmental exposures, understanding
mechanisms of toxicity and disease, and potential therapeutic targets. Created with Biorender.com
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exposures have been fully characterized. Studying the exposome thus relies on cutting-edge tech-
nologies that can detect and identify chemicals we are exposed to, moving beyond a targeted list of
known chemicals of interest. Analysis and interpretation of this data requires various data analyti-
cal techniques: dimension reduction techniques, data integration, network analysis, and longitudi-
nal analysis to name a few. Apart from novel data analytical applications, the field also needs to
think about confounders and effect modifiers when measuring associations between exposure and
disease. For example, how should social class or socioeconomic status be treated in a model - as
a confounder, effect modifier, or a determinant of exposure? Uncovering the exposome will need
input from scientists working in the fields of environmental chemistry, toxicology, exposure sci-
ence, epidemiology, molecular biology, analytic chemistry, bioinformatics, and engineering. Thus,
a multifaceted problem will be best tackled with multi-disciplinary research teams. In this disserta-
tion I have demonstrated that recently developed methods using high-resolution mass spectrometry
provide a tool to interrogate the biological effects of environmental exposures related to disease.
I have demonstrated that this approach works in one of the simplest of biological organisms, C.
elegans, as well as in human populations. I was able to model the effects of specific environmental
exposures on a genetically vulnerable strain of C. elegans and compare those effects to what was
seen in human Alzheimer’s disease. This worm to human comparison has never been conducted
in Alzheimer’s disease and my findings have revealed clues as to the biological pathways that may
mediate the environmentally-related drivers of the disease. In addition to laboratory studies in C.
elegans and metabolic studies in human participants, I also had to apply sophisticated statistical
and bioinformatic approaches to analyze the complex data that resulted from the research. The
workflow I developed can now be applied to larger human populations and more complicated ex-
posures in the worm model. This will allow the systematic analysis of the environmental driver’s
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Appendix A: Metabolomics and air pollution in the WHICAP cohort
While determining the environmental drivers of Alzheimer’s disease, I began to study the role
of air pollution and metabolism to uncover disease related differences in response to exposure.
However, over the course of my research and projects, I did not have sufficient time to complete
this analysis. Here I provide a brief description of the project and progress made to date.
Air pollution remains one of the largest threats to public health. WHO estimates from 2012
found that 1 in 8 deaths worldwide were attributable to air pollution (WHO | 7 million premature
deaths annually linked to air pollution). The elderly are particularly susceptible to the effects of
air pollution and several effects of air pollution manifest in old age (Ward-Caviness et al. 2016).
Using the Washington Heights and Inwood Columbia Aging Project, I plan to assess the relation-
ship between air pollution exposure levels and the plasma metabolome. Further, I will investigate
how underlying disease status can modify the relationship between exposure and the metabolomic
profile (Figure A.1).
Several studies have reported changes in the plasma metabolome associated with exposure to
air pollution, through both epidemiological and toxicological studies. However, few studies have
explored this relationship in the elderly.
The air pollution exposure estimates were made previously by Erin Kulick (Kulick et al. 2020).
Kulick et al estimated levels of residential air pollution exposure in all participants of the WHICAP
cohort. They used regionalized universal kriging models to estimate levels of nitrogen dioxide
(NO2; ppb), fine particulate matter less than 2.5 `m in diameter (PM2.5; `g/<3), and respirable
particulate matter (PM10; `g/<3) at each geocoded address in the calendar year prior to a visit to
the Columbia clinic or hospital. To improve predictions, partial least square methods were used to
include geographic covariates (roadway density, population density, urban land, agricultural land,
forests, bodies of water), land use, and roadway proximity. Further, the NO2 model incorporated
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Figure A.1: Does disease status modify biological response to air pollution exposure?
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Table A.1: Air pollution exposure in cases of Alzheimer’s disease and controls of the WHICAP
cohort









































































satellite data to improve predictions (Kulick et al. 2020).
Of the 119 participants with metabolomics data (Chapter 2), 107 have measures of all air
pollutants (PM2.5, PM10 and NO2, represented by 50 controls and 57 cases of AD (Table A.1). The
year when blood was drawn from the participants ranged from 1994 to 2017 with most participants
having their blood drawn in the year 1995. The distribution over the years appears similar between
cases and controls (Figure A.2).
A.1 Relationship between plasma metabolome and NO2 levels
A single pollutant univariate analysis was conducted to determine features associated with
levels of NO2 in cases and controls. The feature table was cleaned and filtered as described in
Chapter 2. Each feature was generalized log transformed and its intensity was regressed on levels
of NO2, measured as parts per billion (ppb).
In cases of AD, 9 features were significantly associated with FDR < 0.05 (Table A.2) while in
controls, 20 features met this criteria (Table A.3).
A.2 Future plans
For this analysis, to model the association between exposure and the plasma metabolome, I
will adjust for variation that may derive from change over time not related to air pollution and also
run single pollutant models using exposure estimates made for PM2.5 and PM10. The biological
implications of metabolomic changes will be assessed using pathway analysis.
The results will be compared between cases and controls to ascertain how underlying disease
pathology may change the response to air pollution exposure.
The WHICAP cohort provides a unique opportunity to understand the relationship between
air pollution and AD incidence and progression. While this study described above has a small
sample size, metabolomic profiling of all WHICAP participants will provide sufficient power to
understand this interaction between disease pathology and progression, and air pollution.
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Figure A.2: Distribution. Most plasma samples were collected in 1995. The distribution of plasma
collection over years looks similar between cases and controls
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Figure A.3: Univariate analysis. In cases and controls, several features are associated with levels
of NO2 exposure. There are 20 features with an fdr < 0.05 in controls and 9 features in cases.
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Table A.2: In cases, features associated with levels of NO2
determined through a univariate analysis. Annotations are
made through xMSannotator.
mz time V p.value Annotation HMDB ID Xppm
139.4972 266.5 0.093 8.35E-09 unknown
140.8713 61.7 0.069 3.47E-05 unknown
174.0955 80 0.076 1.76E-05
Glycylproline HMDB00721 -
L-prolyl-L-glycine HMDB11178 -





295.2264 40 0.088 3.95E-07





Squamostanal A HMDB29969 1.25
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Table A.2: In cases, features associated with levels of NO2
determined through a univariate analysis. Annotations are
made through xMSannotator.
mz time V p.value Annotation HMDB ID Xppm
295.2264 40 0.088 3.95E-07
(9Z12Z14E)-16-Hydroxy-91214-octadecatrienoic acid HMDB34586 1.25
17-Hydroxylinolenic acid HMDB11108 1.25
A-12(13)-EpODE HMDB10200 1.25
Sterebin D HMDB36832 1.25
2-Hydroxylinolenic acid HMDB31103 1.25
10-Oxo-11-octadecen-13-olide HMDB29786 1.25
(9S10E12Z15Z)-9-Hydroxy-101215-octadecatrienoic acid HMDB31934 1.25
34-Dimethyl-5-pentyl-2-furanheptanoic acid HMDB39603 1.25
(2E4Z8E)-Colneleic acid HMDB30995 1.25
13-HOTE HMDB10203 1.25
1516-Epoxy-912-octadecadienoic acid HMDB30950 1.25





Table A.2: In cases, features associated with levels of NO2
determined through a univariate analysis. Annotations are
made through xMSannotator.
mz time V p.value Annotation HMDB ID Xppm
2-Heptadecanone HMDB31040 1.32
2-Pentadecylfuran HMDB33609 1.32
309.2056 40.5 0.094 1.67E-07
Corchorifatty acid A HMDB32664 1.42









13-L-Hydroperoxylinoleic acid HMDB03871 1.4
()-(E)-13-Hydroxy-10-oxo-11-octadecenoic acid HMDB40900 1.4
8(R)-Hydroperoxylinoleic acid HMDB04706 1.4
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Table A.2: In cases, features associated with levels of NO2
determined through a univariate analysis. Annotations are
made through xMSannotator.
mz time V p.value Annotation HMDB ID Xppm
9(S)-HPODE HMDB06940 1.4
348.2739 32.2 0.092 5.53E-07 unknown
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Table A.3: In controls, features associated with levels of
NO2 determined through a univariate analysis. Annotations
are made through xMSannotator.
mz time beta p.value Annotation HMDB ID delta ppm




127.326 260.1 -0.0913995 1.19E-05 unknown
132.5366 43.3 -0.0781771 1.36E-05 unknown
139.4972 266.5 0.0827676 4.81E-06 unknown
174.0955 80 0.084 1.35E-06
L-Prolyl-l-glycine HMDB11178 -
Glycylproline HMDB00721 -
197.1649 45.3 0.07181711 8.87E-05 20-dihydrodydrogesterone HMDB60729 9.89





290.9819 137.5 -0.0827226 8.44E-05 unknown
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Table A.3: In controls, features associated with levels of
NO2 determined through a univariate analysis. Annotations
are made through xMSannotator.
mz time beta p.value Annotation HMDB ID delta ppm
295.2264 40 0.088 2.57E-07






Squamostanal A HMDB29969 1.25
(9Z12Z14E)-16-Hydroxy-91214-octadecatrienoic acid HMDB34586 1.25
17-Hydroxylinolenic acid HMDB11108 1.25
A-12(13)-EpODE HMDB10200 1.25
Sterebin D HMDB36832 1.25
2-Hydroxylinolenic acid HMDB31103 1.25
10-Oxo-11-octadecen-13-olide HMDB29786 1.25
(9S10E12Z15Z)-9-Hydroxy-101215-octadecatrienoic acid HMDB31934 1.25
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Table A.3: In controls, features associated with levels of
NO2 determined through a univariate analysis. Annotations
are made through xMSannotator.
mz time beta p.value Annotation HMDB ID delta ppm
34-Dimethyl-5-pentyl-2-furanheptanoic acid HMDB39603 1.25
(2E4Z8E)-Colneleic acid HMDB30995 1.25
13-HOTE HMDB10203 1.25
1516-Epoxy-912-octadecadienoic acid HMDB30950 1.25






298.0177 98.9 0.06878396 1.35E-04 unknown
300.261 34.9 0.066 2.36E-05
3-Oxooctadecanoic acid HMDB10736 -
Ricinoleic acid HMDB34297 -
5-Oxooctadecanoic acid HMDB34074 -
11-Oxooctadecanoic acid HMDB30981 -
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Table A.3: In controls, features associated with levels of
NO2 determined through a univariate analysis. Annotations
are made through xMSannotator.
mz time beta p.value Annotation HMDB ID delta ppm
10-Oxooctadecanoic acid HMDB30980 -
9-Oxooctadecanoic acid HMDB30979 -
5-Hexyltetrahydro-2-furanoctanoic acid HMDB31127 -
309.2056 40.5 0.074 3.05E-05
Corchorifatty acid A HMDB32664 1.42









13-L-Hydroperoxylinoleic acid HMDB03871 1.4
()-(E)-13-Hydroxy-10-oxo-11-octadecenoic acid HMDB40900 1.4
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Table A.3: In controls, features associated with levels of
NO2 determined through a univariate analysis. Annotations
are made through xMSannotator.
mz time beta p.value Annotation HMDB ID delta ppm
8(R)-Hydroperoxylinoleic acid HMDB04706 1.4
9(S)-HPODE HMDB06940 1.4
316.2843 25.9 0.05309653 9.32E-05 Dehydrophytosphingosine HMDB38057 1.01
329.2318 42.3 0.070 1.46E-04
(9R10S12Z)-910-Dihydroxy-8-oxo-12-octadecenoic acid HMDB40611 1.37
Corchorifatty acid F HMDB35919 1.37
Auxin a HMDB38483 1.37
348.2739 32.2 0.08066876 3.62E-06 unknown
366.3364 25.1 0.07467536 8.38E-05 unknown
473.0206 116 -0.0841704 1.12E-05 Benzthiazide HMDB14702 6.93
839.9052 79.5 0.07453106 5.44E-05 unknown
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Appendix B: High-resolution metabolomics in C. elegans: method
optimization
In this appendix, I present data and findings made during optimization of the global high-
resolution metabolomics (HRM) assay in C. elegans.
Geier et al (Geier et al. 2011) compared results across different platforms and techniques for
metabolite extraction. They found that the solvent chosen for extraction influenced the levels of
metabolites detected more than the tissue disruption technique chosen. Through their comparative
analysis, they concluded that using 80% methanol and a bead beater afforded the “best” trade-off.
In order to maintain the ability to compare metabolomic measurements made across samples run
on the same instrument at the Clinical Biomarker lab at Emory University, we chose to use the
same extraction solvent, used successfully to extract metabolites from human samples, and used
the bead beater to disrupt the cuticle and worm tissue.
Based on the finding from Geier et al. (Geier et al. 2011) and extraction procedures at the
Clinical Biomarker Lab at the time, we chose to perform the assay in the following way:
B.1 Sample growth and collection
Worm strains were grown in liquid culture or on agar plates to the desired age or with the
desired exposure. Worms were collected and washed in M9 to remove any remaining bacteria
or media. Once washed, worms were sorted using a COPAS biosorter by gating the length and
density of the worms that met inclusion criteria for a certain stage. Around 500 worms were
aliquoted to form one sample and the appropriate number of replicates per group were collected.
Blank samples were also collected that represented the buffered media (M9) used to wash and sort
the worms. Soon after collection, worms were spun down using a table top centrifuge and the
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volume of M9 was reduced down to 100`l. The worm samples were then snap frozen in liquid
nitrogen and stored at -80◦C until needed for processing.
B.2 Samples processing for metabolite extraction
Samples for analysis were removed from the -80◦C freezer and allowed to thaw on ice. Aliquots
of a pooled reference material were also thawed and processed similarly to the worm samples.
Once thawed, 200`l of acetonitrile, spiked with an internal standard containing stable isotope
standards of 13 metabolites found endogenously, was added to every sample and the pooled refer-
ence. The samples were then vortexed for about 30 seconds and to all the worm samples, a spatula
full ( 10 beads) of zirconium oxide beads (0.5mm, Yttria stabilized) from Next Advance (Troy,
NY) was added. The tubes with samples and beads and the pooled reference material tubes were
then placed in a Next Advance Bullet Blender, operated in a cold room, at 6.5 m/s speed for 30
seconds. After a minute of equilibration on ice, the tubes were placed in the bead beater at the
same setting one more time. After bead beating, the samples were allowed to equilibrate on ice for
30 minutes. They were then centrifuged at 15,000 xg for 10 minutes. 100 `l of the supernatant
was placed in LC vials for LC-HRMS analysis at the Clinical Biomakers Lab at Emory University.
Growth and number of worms for HRM. To assess the effect of growth conditions on
metabolism, wildtype worms were grown either in liquid culture or agar plates and collected for
analysis. Further, from each growth condition, a series of samples were collected with 100, 250,
500, or 1000 worms. With 3 replicates of each group, we analyzed the global metabolome mea-
sured using the LC-HRMS method and found that as the number of worms increased, the intensity
of endogenous metabolites increased (Figure B.1 A and B). Further, there was not a significant
difference between levels of the M+H adduct of tyrosine measured in samples with 500 worms
grown on agar plates or in liquid culture. Based on these findings, we proceeded with collected
500 worms per sample for analysis since it gave a robust signal in both growth conditions.
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Figure B.1: Growth and numbers for HRM. In A, levels of the M+H adduct of tyrosine across
different worm numbers when grown in liquid culture. The level of the feature increases as the
number of worms increases. In B, levels of the same adduct as in A but with worms grown on agar
plates. The log2 transformed intensity of the feature in the 500 worm dilution looks similar across
the two growth conditions (dashed line).
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B.3 Chromatographic and mass spectrometric settings
The chromatographic method has been described previously (Soltow et al. 2013; Go et al. 2015a).
In brief, analyte separation is accomplished using hydrophilic interaction chromatography (HILIC)
under positive ESI, reversed phase chromatography using a C18 column under negative ESI and a
Dionex Ultimate 3000 pump operated at 0.5mL/min with water, acetonitrile and solution A (5%
[v/v] formic acid in water) mobile phases operating under the following gradient: 10% water, 80%
acetonitrile, 10% solution A hold for 0.5 min, linear gradient to 80% water, 10% acetonitrile, 10%
solution A at 2 min, and hold for 3 min, resulting in a total run time of 5 min. The electrospray
ionization source is operated with spray voltage of 3.5 kV, probe temperature of 300°C, capillary
temperature of 300°C, sheath gas flow of 45 (arbitrary units), auxiliary gas flow of 25 (arbitrary
units), sweep gas flow of 1 (arbitrary units), and S-lens RF level of 45%. In full scan mode, the res-
olution is set to 120,000 (FWHM) and a mass-to-charge ratio (m/z) range of 85.0000-1275.0000.
After completion of LC-HRMS analysis, mass spectral features with replicate coefficient of vari-
ation (CV) ≤ 100% are extracted and aligned using apLCMS (Yu et al. 2009a) with xMSanalyzer
(Uppal et al. 2013); batch effects are then corrected with ComBat (Leek et al. 2012).
B.4 Trials with the daf-16 mutant
In C. elegans, the daf-16 gene encodes for the DAF-16/FOXO transcription factor which is
a key transcription factor that is thought to integrate signals from pathways like the insulin/IGF-
1 signaling pathway, TOR signaling, AMPK pathway, JNK pathway and germline signaling to
modulate aging, and longevity via shuttling from cytoplasm to nucleus (Sun, Chen, and Wang
2017). I investigated changes in global metabolism associated with the daf-16 mutant using our
LC-HRMS platform.
It has been reported that the strain has increased oxidative stress, which guided us to assess
the levels of glutathione measured in the worm. We assayed levels of glutathione in two ways: 1.
Through a targeted HPLC assay and 2. Through the HRM assay.
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Targeted HPLC. Measurement of reduced and oxidized glutathione was done using a protocol
described by Jones et al. (Jones et al. 1998), adapted for C. elegans. 500 worms per strain were
collected using a Union Biometrica COPAS biosorter (Holliston, MA) into 50`l of preservation
buffer (5% (w/v) perchloric acid containing 0.2 M boric acid and 10mM W-glutamylglutamate was
added immediately after collection. Samples were snap frozen in liquid nitrogen and stored at -80
◦C. On the day of analysis, samples were allowed to thaw, and sonicated on ice using 12 pulses
at 50% amplitude for 5 seconds with a 2 second break. The samples were centrifuged at 13,000
rpm for 2 minutes. 300 `l of the supernatant was then transferred to a 1.5 ml microfuge tube
and processed as described by Jones et al (Jones et al. 1998). Briefly, 60 `l of iodoacetic acid
solution (made by adding 14.8 mg of iodoacetic acid per 2 ml of distilled water) was added to each
tube. A potassium hydroxide (KOH)/tetrahydroborate solution (prepared by adding 5.6 g KOH
to a plastic bottle containing 50g tetrahydroborate and 100 ml water) was used for adjustment of
pH to 9.0 ± 0.2. After 20 minutes of incubation at room temperature, 300 `l of 20 mg/ml dansyl
chloride solution in acetone was added. The samples were vortexed and placed in the dark for 24
hours. After incubation in the dark, 500 `l of chloroform was added to each sample and vortexed.
Samples were centrifuged at 10,000 rpm for 2 minutes to separate the organic and aqueous phase.
The upper aqueous layer was collected into HPLC vials. For HPLC analysis, 20 `l of each sample
was injected onto a 3-aminopropyl column. All analysis parameters replicate those listed in the
Jones et al protocol (1998). Quantitation of reduced and oxidized glutathione were obtained by
peak integration relative to the internal standard.
We found increased levels of reduced glutathione and reduced redox potential in the daf-16
mutants assessed using the targeted HPLC assay. The M+H adduct of glutathione measured on the
LC-HRMS system was also lower in the daf-16 mutant compared to wildtype (Figure B.2 A and
B).
We analyzed the global metabolic profile of the daf-16 mutant and found several metabolites
significantly different with FDR < 0.05 (Figure 3 A). These features enriched several pathways as-
sociated with amino acid metabolism and energy production. Further, the glutathione metabolism
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Figure B.2: Glutathione levels. The daf-16 mutant is a short-lived strain with alterations in several
aspects of its metabolism. In A, we measured levels of reduced glutathione using a targeted HPLC
assay and found higher levels of reduced glutathione compared to wildtype worms. In B, using our
untargeted HRM approach, the M+H aduct of glutathione showed a similar increase in levels of
reduced glutathione. Thus, data from both analyses point to increased levels of reduced glutathione
in the mutant strain.
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Figure B.3: The metabolomic profile of daf-16 mutants. A. T-tests of mz/RT pairs, pink features
are significantly different at FDR < 0.05. B. PLS-DA regression showing separation of features
measured in daf16 (red) and N2 (green). C. Top pathways altered, as predicted by mummichog
software. D. Network modules that may capture concerted metabolites activities, which may not
be represented by predefined pathways.
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pathway was also enriched. Network module analysis performed through mummichog suggested
changes in alanine and xanthine metabolism associated with change in glutamate metabolism (Fig-
ure B.3).
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